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Abstract  
 
Tendon plays an important role in regulating body locomotion and providing 
additional stability to the body. However, tendon is susceptible to injuries and the 
healing process could be devastating along with the several issues, namely 
adhesion formations, slow healing and failure at fixation sites, which have 
deferred the success of proper tendon healing via tendon tissue engineering. This 
dissertation thus aims to create a sustained dual-drug therapy to address these 
issues. For adhesion formation, naproxen sodium (NPS) has been shown to be 
able to avoid this symptom through inhibiting inflammation process. Therefore, 
so as to eliminate the side effects of NPS such as drowsiness, headache and 
nausea, NPS was loaded into an electrospun aligned poly (l-lactic acid)/poly (ε-
caprolactone) scaffold and its release from the scaffold was optimized to achieve 
controlled release through adjusting the polymer compositions and water 
percentage in hexafluoroisopropanol (HFIP). A 2-week sustained release was 
achieved through modulating the NPS distribution in the fibers of a scaffold 
which possesses aligned morphology and optimal mechanical properties. Notably, 
the scaffold exhibited no cytotoxicity and tenocytes could respond to the 
topographical cues given by the scaffolds, forming a network of cells which 
mimic the native tendon tissue arrangement. Although NPS is needed to prevent 
adhesion formations, it has been shown to inhibit the proliferation of tenocytes. 
Hence the second objective of this dissertation is to release growth factor to 
promote cell proliferation, and at the same time tackle on the slow healing issues 
during tendon healing. Insulin-like growth factor 1 (IGF-1) was thus loaded into 
electrospun poly (lactic-co-glycolic acid)/poly (ε-caprolactone) aligned scaffolds 
for its ability to promote cellular proliferation and maturation. HFIP was 
identified as the electrospinning solution for its ability to better maintain IGF-1 
stability. The released IGF-1 was shown to have maintained its bioactivity and 
could trigger downstream cellular response such as promoting tenocytes 
proliferation and up-regulating the tendon specific gene markers expression (i.e. 
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scleraxis and tenomodulin). Most importantly, the released IGF-1 has 
compensated the inhibitory effect of NPS, through enhancing the proliferation and 
differentiation of tenocytes on the combined scaffolds (which were fabricated 
through sequential electrospinning of NPS scaffolds and IGF-1 scaffolds). In 
addition, IGF-1 scaffold has been utilized as the platform to tissue engineer 
C2C12 murine myoblast, tenocytes and TE85 human osteosarcoma together, with 
the intention of enhancing interaction between different cells in order to solve the 
issue of failure at the fixation sites, where regeneration is difficult at this 
translation region. Through medium compatibility optimizations, three types of 
cells could proliferate and differentiate in a common medium, in which their 
configuration on the scaffold mimicked the actual musculoskeletal tissue 
arrangement in the body. These results indicate that the scaffolds have promising 
potential in enhancing tendon regeneration in vivo, with their IGF-1 and NPS 
releasing abilities and desirable tendon TE characteristics. 
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Chapter 1  
 
Introduction 
 
This chapter introduces the current state of the art of tissue engineering (TE) 
in promoting tendon regeneration and the encountered issues during the 
tendon healing via TE approach. Issues were identified and the solutions 
were proposed, as the motivation of this developmental dissertation. Key 
activities of each proposed works are listed out to achieve a specific 
objective and therefore prove the hypotheses. Finally, the outline of this 
dissertation is presented, followed by the findings of the dissertation in the 
last section of this chapter. 
 
.
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1.1 Background and problem statement 
 
There are millions of musculoskeletal injuries involving the impairment of tendon and 
ligament reported annually 
1
. Due to low vascularity and cellularity 
2
, spontaneous tendon 
healings usually results in reduced functional tissues 
3
. This could be devastating 
especially for athletes, in additional to the pain and discomfort that need to be endured 
during the healing process. 
 
Sufficient rest and medical intervention are necessary when the tendon injury is mild. 
Generally patients are advised not to conduct aggressive activities and sometimes 
medicines such as non-steroidal anti-inflammatory drug (NSAID) 
4
 or corticosteroids 
5
 
will be prescribed to relieve the symptoms of the injury. For severe tendon damage, 
besides medicine prescription, surgical intervention has become the gold standard for 
tendinopathies 
6
. Nonetheless, there are insufficient successful cases in which grafts could 
fully heal injured tendons, as arising issues such as increased inflammatory response, 
antigenic reactions and lack of long term biocompatibility have limited their application 
in treating tendinopathies widely 
7-9
. Notably, the postoperative adhesion formation 
often results in interference of tendon gliding and might eventually lead to partial 
loss of function of the repaired tissue and recurrent injury 
10
. Adhesion formation 
refers to abnormal adherence between the sheath and tendon 
11
. One of the promising 
solutions to avoid adhesion formation is the use of NSAIDs 
12
. In particular, naproxen 
sodium (NPS) has been widely prescribed to tendonitis patients due to its analgesic 
effects 
13
 and its ability to prevent adhesion formation 
14
. It should be noted that sustained 
releasing systems for NPS are always desirable in order to eliminate its adverse effects 
e.g. nausea, diarrhea and drowsiness 
15
. 
 
For proper tendon healing, tendon tissue engineering (TE) is a promising field which 
seeks to generate solutions for tendon regeneration. Biodegradable synthetic polymers 
such as poly-lactide (PLA), poly-glycolide (PGA) and poly(lactide-co-glycolide) (PLGA) 
are widely used in scaffold fabrication for their ease of processing, reproducibility and 
better mechanical properties 
16-18
. In processing these polymers into scaffolds for TE, 
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electrospinning stands out as a relatively simple technique to produce continuous fibers 
such that the resulting scaffold possess the desired interconnected pores to allow tissue 
integration and diffusion of nutrients 
19-21
. However, these electrospun bio-mimicking 
fibrous structures often lack of bioactivity which is required to promote adequate tendon 
regeneration 
22
. To address this issue, current research has been focusing on the use of 
chemical stimulation which involves using molecules or growth factors (GFs) to enhance 
tendongenesis 
21
. For instance, platelet-derived growth factor (PDGF) and insulin-like 
growth factor 1 (IGF1) have been widely utilized to promote proliferation of tenocytes 
and trigger the synthesis of collagen 
23,24
. Despite the beneficial roles of GFs in 
promoting tendon healing, their susceptibility towards degradations in vivo 
(including denaturation, oxidation and proteolysis) has limited their usage in actual 
medical practices 
25
. Therefore, as a whole, a tendon regenerative platform should have 
a good combination of several criteria such as appropriate morphological environment 
and sufficient biochemical cues. 
 
In addition, despite numerous researches have been emphasized on the repair of the 
tendon tissue, the restoration of the intricate structure between tendon and bone 
(osteotendinous junctions) or tendon and muscle (myotendinous junction) has always 
been neglected. Being structurally different, this translational part, which serves as the 
stress concentration at the interface, is always prone to severe or overuse injuries in 
sports, such as tennis elbow and jumper‘s knee 26. Therefore, in the attempts of re-
attaching the tendon to the bone or muscle part, there is high probability of failures at 
these fixation sites due to the fact that the unique transitional tissue between the 
muscle, tendon and bone generally fail to regenerate during healing
27-29
. 
 
In view of the complex considerations in tendon healing, it is desirable that a scaffold not 
only possesses the TE criteria as mentioned earlier, but also the ability to release NSAIDs 
and GFs sustainably. Therefore, it would be useful to investigate the possibility of 
fabricating a scaffold which combines both tissue engineering and drug delivery of NPS 
and GFs, and its potential for tendon healing, as well as the regeneration of the unique 
translational tissue between muscle-tendon-bone. 
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1.2 Objectives and scope 
 
The general objective of this dissertation is to address the following issues which might 
defer the success of tendon healing through TE approach: 
 
1) Issue 1: “The postoperative adhesion formation often results in interference of 
tendon gliding and might eventually lead to recurrent injury or partial function loss 
of repaired tissue.” 
 
In the attempts of tendon healing, other than the necessary TE criteria as mentioned 
earlier, it is essential to consider the issue of adhesion formations during the healing 
process. NPS, which can relieve the pain symptoms and prevent fibrous adhesions, has 
been identified as a promising solution. However, the attempts were not entirely 
successful in releasing NPS sustainably in hydrophobic matrices 
30-32
 because of its low 
molecular weight and the hydrophilic nature. The first part of this dissertation therefore 
proposes to fill this gap through a combination of obtaining sustained release of NPS and 
using of TE approach to better heal tendinopathies. It is postulated that different solvent 
systems could affect drugs distributions within electrospun fibers and thus affecting their 
release. It is therefore of interest to investigate the possibility of releasing NPS 
sustainably by optimizing the solvent system and polymer ratios of the electrospun fibers, 
and eventually evaluate the ability of the scaffold for tendon regeneration.  
 
Therefore, for this part the specific objective is to achieve sustained release of NPS in a 
fibrous scaffold which possesses tendon TE characteristics such as aligned morphology 
and optimal mechanical properties.  
 
It is hypothesized that sustained release of NPS could be achieved in electrospun fibrous 
system through affecting the drug distribution in the fibers via modulating the 
formulations of the electrospinning solutions  
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Key activities: 
 Fabricate NPS electrospun scaffolds with tendon TE characteristics by variation of 
electrospinning controlling parameters; 
 Achieve sustained release of NPS through optimizing the 1) polymer compositions; 
and  2) co-solvent percentage; 
 Study the factors affecting the NPS release through analyzing fibers diameter, 
scaffold hydrophilicity and drug distribution; 
 Evaluate the characteristics of scaffolds for tendon healing from their mechanical 
properties and cell compliance study. 
 
2) Issue 2: “Despite the beneficial roles of GFs in promoting tendon healing, their 
susceptibility towards degradations in vivo (including denaturation, oxidation and 
proteolysis) has limited their usage in the actual medical practices” 
 
Owing to the beneficial roles of GFs in promoting tendon healing and the detrimental 
side effects for uncontrolled GFs delivery, numerous efforts have been done to 
incorporate GFs into matrices to achieve controlled release of GFs for tendon 
regeneration 
33-36
. One of the main challenges is that the entrapment processes which 
involve the use of organic solvents would deteriorate the protein stability 
37,38
. Recent 
reports on the feasibility in persevering the ordered peptides secondary structure in 
hexafluoroisopropanol (HFIP)-based solution has highlighted the possibility of using 
HFIP as the solvent in electrospinning GFs 
39
, in addition to the fact that HFIP-based 
solutions can minimize the notorious protein denaturation which occurs at the organic-
inorganic interfaces 
40-42
. The second part of this dissertation would thus investigate the 
feasibility of using HFIP as the electrospinning solvent for GFs delivery in tendon TE.  
 
The specific objectives of this part is thus to incorporate GFs (insulin-like growth factor 1, 
IGF-1 as identified in this dissertation) in an electrospun fibrous system and achieve 
controlled release of IGF-1 to promote cellular responses. 
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It is hypothesized that the bioactivity of entrapped IGF-1 in hydrophobic polymer 
electrospun matrices could be better preserved through the use of HFIP as the solvent for 
electrospinning. 
 
Key activities: 
 Fabricate the IGF-1 aligned scaffolds with tendon TE characteristics; 
 Correlate the relationships between the polymer concentration/compositions with the 
release of IGF-1 from the electrospun fibrous scaffolds; 
 Examine the biological activity of the IGF-1 released from electrospun scaffolds with 
the use of western blotting technique; 
 Evaluate the effect of released IGF-1 on the downstream cellular responses, such as 
proliferation and differentiation 
 
3) Issue 3: “Failures at these fixation sites due to the fact that the unique transitional 
tissue between the muscle, tendon and bone generally fail to regenerate during 
healing” 
 
In order to improve the improper regeneration at the intricate junctions between muscle-
tendon-bone, many efforts such as improving suturing techniques 
43-45
, use of GFs 
46-49
 
and mesenchymal stem cells 
50
 have been attempted. However in interface TE, most 
studies focused on scaffolds designs 
51
; while the culture conditions for growing different 
tissue types have been inadequately addressed. In view of the fact that in vitro models 
were much more preferred in order to better manipulate cell fate prior to implantation 
52
, 
the last part of this dissertation hence proposes the use of GFs-loaded scaffolds to 
optimize the culture environments for growing different tissue types, namely myoblasts, 
tendon cells and osteoblasts. 
 
The specific objective of this part is to optimize the culture conditions for growing three 
types of cell (namely C2C12, tendon cells and TE85) in one common platform, which is 
the use of IGf-1 scaffolds.  
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Key activities: 
 Develop a same culture condition where C2C12, TE85 and tenocytes could survive 
and proliferate; 
 Ensure the C2C12, TE85 and tenocytes could undergo differentiation properly; 
 Tri-culture the cells on IGF-1 scaffolds 
 
1.3 Dissertation outline 
 
The issues encountered during the tendon healing have been discussed in Chapter 1 to 
further support the rationale and objectives of the dissertation. In Chapter 2, a review on 
the tendon structures, current treatments and how tissue engineering could help in tendon 
regeneration have been discussed. Elaboration of materials and methods utilized in this 
work will be presented in Chapter 3. For Chapter 4, the feasibility of achieving sustained 
release of NPS from electrospun fibrous scaffolds were explored through modulating the 
polymer compositions and solvent ratios. Afterwhich, IGF-1 was incorporated into 
fibrous scaffolds and the studies regarding the bioactivity of IGf-1 and downstream 
cellular responses were explored in Chapter 5. In Chapter 6, culture medium 
compatibility optimization was carried out to tri-culture the three types of cells on the 
IGF-1 scaffolds, in anticipating to achieve an in vitro musculoskeletal model. Finally, 
Chapter 8 concluded the work in this dissertation with recommendations on future work. 
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1.4 Findings and outcomes/originality 
 
This research led to several novel outcomes: 
1. Achieving sustained release of NPS in electrospun fibrous scaffolds with tendon 
TE characteristics by affecting the drug distributions via modulating the polymer 
compositions and the percentage of co-solvent (i.e. water) used. 
2. Preserving IGF-1 bioactivity in an electrospun hydrophobic scaffold and 
successfully promoting tendon cells proliferation and differentiation under the 
influence of released IGF-1. In addition, the released IGF-1 has rescued the 
proliferation of tendon cells on combined scaffolds, where the released NPS could 
have some inhibitory effects on cellular response. 
3. Establishing an in vitro tri-culture system where three types of cell, namely 
C2C12, tenocytes and TE85 could proliferate and differentiate, through the 
culture medium compatibility optimization. 
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Chapter 2  
 
Literature Review 
 
This chapter comprises of 4 sections. The first section introduces the 
structure and function of the tendon, followed by tendinopathies and the 
healing process involved. The second section would summarize the current 
methods in treating tendon injuries and the associated issues. These bring 
out the third section which discusses how tissue engineering contributes to 
the tendon healing via four approaches, namely scaffolds, cells, chemical 
stimulation and mechanotransduction. Lastly, the fourth section highlighted 
the importance in enhancing osteotendinous and myotendinous junctions 
repair in order to achieve better tendon healing. 
 
.
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2.1 Tendon  
 
2.1.1 Structure and function 
 
A tendon (or sinew) is a fibrous connective tissue in a form of tough band which links 
bone to muscle. Healthy tendons are made up of arrays of collagen fibers (mainly type I 
collagen) parallel to each other, along with 1–5% proteoglycans, 2% elastin, , and 0.2% 
inorganic components such as manganese, copper and calcium 
1
. Being encased in dense 
irregular connective tissue sheath, tendon is assembled hierarchically from collagen 
molecules to form fibrils, fiber bundles, fascicles and tendon units eventually 
2
. There are 
two main types of cells in tendon: tenoblasts and tenocytes. Tenoblasts have spindle 
shaped morphology and many cytoplasmic organelles. They mature into tenocytes, which 
are morphologically identical to fibroblasts 
3,4
. Tenocytes detect and respond to 
mechanical loading through gap junctions formed between them 
5
. 
 
Figure 2.1: Schematic diagram of the structure of tendon 
 
The closely packed collagen fibrils which show a wave-like appearance or ―crimp pattern‖ 
play a pivotal role in their mechanical properties 
2
. During tendon stretching, due to 
crimps development in the collagen fibrils, tendons behave like soft tissue and are more 
stretchable than ligaments. They allow tendon to withstand tensile stress, while 
proteoglycans are able to withstand compressive stress 
6
. Other than simply transmitting 
forces, tendons also provide additional stability during locomotion as well as storing and 
recovering energy. 
Literature Review  Chapter 2 
15 
 
2.1.2 Sports injuries, tendinopathies and healing process 
 
Regular exercise could bring benefits to the body, however, even regular careful exercise, 
does come with risks. Most people only experience minor sports-related injuries such as 
strained muscles and blisters. A few will experience more serious injuries such as torn 
cartilages or tendon sports injuries. 1 of every 10 people and 1 of every 2 runners are 
afflicted with tendon injuries. In addition, tendons are also susceptible to various kinds of 
injuries or tendinopathies due to intrinsic factors such as age, nutrition and body weight 
or extrinsic factors such as excessive loads and environmental conditions. Tendinopathies 
can be classified into four types. Paratenonitis, as the first type, is considered when the 
inflammation occurs at paratenon or paratendinous sheet 
7
. At the cellular level, if the 
tendon injury is non-inflammatory, it is classified as tendinosis 
8
. Third type would be 
paratenonitis with tendinosis, which refers to combination of tendon degeneration and 
paratenon inflammation while for the fourth type, tendinitis refers to vascular disruption 
besides degeneration with inflammation of the tendon 
9
. Different injuries result in 
various degrees of inflammation and degeneration of tissues, which may eventually lead 
to tendon rupture. 
 
For tendon healing, there are three main stages which include inflammation, proliferation 
or repair, and remodeling. In the inflammation stage (which lasts for few days), 
inflammatory cells like neutrophils, erythrocytes, monocytes and macrophages are firstly 
recruited, followed by angiogenesis as well as proliferation and migration of tenocytes to 
injury site to produce collagen III 
8,10
. At the second stage, tenocytes continue secreting 
collagen, proteoglycans and GAGs at the injury site. Associating with collagen, 
proteoglycans (e.g. decorin) and GAGs (e.g. chondroitin sulfate and dermatan sulfate) are 
responsible for tendon development by playing important roles in the fibril assembly 
process 
2
. At remodeling stage, production of collagen and GAGs will be reduced. This 
part will take about six to ten weeks and the tissue becomes more fibrous. During the 
second part of the remodeling stage, aligned collagen fibrils start to crosslink, and 
forming stiffer and scar-like tissue 
8
. 
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2.2 Current treatments 
 
Spontaneous tendon healing is possible. However, the formation of scar tissue which has 
smaller crimp pattern with different orientation results in mechanically weaker tissue 
11
. 
Furthermore, the imperfect integration at tendon-tendon or tendon-bone interfaces due to 
fibrous adhesions would have reduced the functionality of repaired tendon through 
limiting tendon gliding and excursion 
12,13
. In additional to the long term pain and 
discomfort which have to be endured by the patients, several issues such as degenerative 
changes, compromised functionality, reduced joint stability and possibility of re-rupture 
are often reported on self-healing tendon 
14
. 
 
2.2.1 Medicinal intervention 
 
There are two conventional ways for tendinopathies management: conservative and 
surgical. Conservative management refers to sufficient rest and medicinal intervention, 
e.g. corticosteroids injections. During the healing process, collagen will be produced to 
recover the continuity of injured tendon fibrils. However, there will be a surge of 
inflammatory cells present at the injury site at the same time. This leads to scar tissue 
formation due to undesirable integration with the fibrils between the sheath and tendon. 
As a consequent, the scar tissue will interfere with the tendon gliding function and thus 
leads to partial loss of tendon function and recurrent injury 
10
. The use of non-steroidal 
anti-inflammatory drugs (NSAID), like naproxen sodium, was found to be effective in 
preventing the adhesion formation during tendon healing. 
 
2.2.2 Surgical intervention 
 
Surgical intervention has been the alternative for tendon treatment when the damage is 
extensive. Various kinds of therapeutic options have been attempted, including autografts, 
allografts and prosthetic devices. However, allografts are expensive, limited and possess 
the risk of immune rejection 
15
 while autologous grafts are often associated with certain 
degree of donor morbidity 
16
. Although artificial implants are relatively successful, the 
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issues like antigenic reactions, the lack of long term biocompatibility, increased 
inflammatory response and failure at fixation sites have limited their application in 
treating tendinopathies 
17-19
. Hence, there is an increasing focus on tendon tissue 
engineering which aims to induce tendon self-regeneration.  
 
2.3 Tendon tissue engineering (TE) 
 
2.3.1 Scaffolds 
 
A three dimensional scaffold housing the appropriate cells is essential to produce a 
construct with the aim of regenerating new tendon tissue. Besides, scaffolds must not 
elicit cytotoxic response and should be biocompatible. In addition, the degradation rate 
should match the rate of neotissue formation while the materials used has to be 
bioresorbable such that the by-products could be expelled out naturally from the human 
body through metabolic pathways 
20-23
. Other than proper surface chemistry to allow 
attachment of cells and also porous structure to facilitate tissue integration and nutrients 
diffusion 
24-26
, the mechanical properties of scaffold should be able to support loading and 
match with functional tissue 
27
. In tendon TE, scaffolds are generally made up of natural 
materials and synthetic polymers. Giving examples of using natural scaffolds, 
mesenchymal stem cells (MSCs)-seeded collagen gel in Achilles tendon defect of rabbits 
has demonstrated improvement in biomechanics and structure 
28
. In another study, 
fibroblast-seeded chitosan-based hyaluronan composite fiber scaffolds has achieved 
better mechanical properties as well as collagen I production compared to acellular 
controls 
29
. However, natural scaffolds lack of adequate mechanical properties for long 
term in vivo usage and hence it is relatively hard to reconstruct the complex architectural 
structure of the native tendon 
30
. 
 
Unlike natural polymers, synthetic biodegradable polymers especially those with 
saturated poly-α-hydroxy esters such as poly-lactide (PLA), poly-glycolide (PGA) and 
poly(lactide-co-glycolide) (PLGA) are much more preferred in tendon TE, due to their 
ease of processing into desired shape with appropriate architectural structure, pore 
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frequency and better mechanical properties. Among various processing techniques, 
electrospinning, which uses electrical charge to draw fibers from polymer solutions, 
stands out for its relatively simple setup to obtain scaffolds with continuous submicron to 
millimeter fibers with high surface-area-to-volume ratio and interconnected pores 
31
. 
These advantages have shown the potential of electrospinning scaffold for tendon healing. 
Sahoo et al. demonstrated bone marrow stromal cells seeded onto a combination of 
knitted PLGA scaffolds with PLGA electrospun nanofibers proliferated faster and having 
higher expression of decorin, collagen I and biglycan genes compared to co-knitted 
PLGA scaffolds 
32
. Notably, aligned fibers which could be easily modulated in 
electrospinning have shown potential tendongenesis in human tendon stem/progenitor 
cells 
33
. A recent dual scaffolding system has shown the potential of using co-electrospun 
poly(L-lactide)/collagen and poly(e-caprolactone)/collagen scaffold to regenerate muscle-
tendon junctions for tendon TE 
34
. Though 80% recovery in mechanical properties of the 
repaired tendon could be achieved by using tenocytes-seeded PGA fibers, this sub-
optimal functionality is not perfect especially for athletes who usually hope for a full 
recovery 
35
. This has suggested that produced bio-mimicking structures are not sufficient 
in promoting tendongenesis, and other factors such as appropriate cell types should also 
be taken into consideration in tendon TE. 
 
2.3.2 Cells 
 
In tendon TE, using autologous or allogenic tendon cells for therapeutic repair could be 
quite challenging. The yield of tendon cells extracted is very low and tenocytes tend to 
de-differentiate in vitro 
36
. Recently, tendon stem/progenitor cells which have been 
recently isolated by Bi et al. have shed a new light on using autologous or allogenic cells 
for tendon TE 
37
. Besides autologous cells, much research has been carried out to 
investigate the possibility for pluripotent embryonic stem cells (ESCs), multipotent 
mesenchymal stem cells (MSCs) and pluripotent cord blood stem cells (SCSCs) to 
differentiate into tenocytes. For example, autologous MSCs have been utilized to enhance 
tendon tissue repair 
38
. However, separate study showed that autologous bone marrow-
derived MSCs were not adequate to regenerate fully functional tendon tissue in rabbit‘s 
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model 
39
. In view of these, stimulations have been used to enhance tendongenesis. 
 
2.3.3 Chemical stimulations 
 
Chemical stimulation has been the most effective method to enhance tendongenesis 
because a variety of molecules or growth factors (GFs) are involved actively in tendon 
healing. During the early stage of healing process, insulin-like growth factor 1 (IGF-I) 
could promote the collagen synthesis and proteoglycans secretions while PDGF could 
enhance DNA synthesis and tendon cells proliferation 
2
. Basic fibroblast growth factor 
(bFGF) was found to have enhanced collagen III production and cell proliferation in rat 
patellar tendon model 
40
. In addition, as members of transforming growth factor beta 
(TGF-β) families41, bone morphogenetic proteins (BMPs) have also been widely accessed 
and shown promising results. For instance, addition of BMP-12 influenced fibrogenesis 
which might have regulated the ECM deposition. Interestingly, other than up-regulating 
the specific growth factors, there are numerous efforts have been done to suppress TGF-
β1 which causes adhesion formation in tendons and reduces the functionality of the 
repaired tissue. 
 
Recent advancements have led to the development of scaffolds which combine good 
structural characteristics with capabilities to release GFs sustainably. The current 
approach to load GFs can be categorized as attachment or encapsulation techniques. To 
attach GFs on the polymeric scaffolds, various ways such as physical adsorption or 
chemical crosslinking have been extensively researched. For instance, GFs which have 
with heparin binding sequences will covalently crosslink to fibrin and the release could 
be realized passively through simultaneous degradation of fibrin/heparin. As for 
entrapment method, which is more preferential due to its simplicity, slower release of 
entrapped GFs could be achieved when the ―polymer capsule‖ degrades, either by surface 
eroding or bulk eroding. Among various systems such as hydrogels, microspheres and 
porous solid scaffolds, electrospinning has predominantly been focused in GFs releasing 
because it simply allows direct loading of GFs into fibers and could achieve high drug 
loading efficiency 
42
. However, rapid release and denaturation of GFs at the oil/water 
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interface 
43
 are even inevitable although different kinds of electrospinning have been 
attempted, like blending electrospinning, emulsion electrospinning or coaxial 
electrospinning 
44
. To rectify these issues, different approaches have been attempted such 
as preloading of GFs into micro/nanospheres or proteins in gentle environment prior to 
adding into electrospun fibers. For example, bFGF-loaded dextran glassy nanoparticles 
inside electrospun poly-l-lactic acid fibers were shown to have longer release for nearly 
30 days while maintaining the bioactivity of bFGF at the same time 
45
. 
 
2.3.4 Mechanotransduction 
 
As an alternative, several researches have been accessing the possibility of mechanical 
stimulation in enhancing tendon healing. Tendon cells, which are mechanosensitive, can 
respond to mechanical stimulations and alter their cell phenotype, genes expression and 
proteins synthesis 
46
. It has been shown that there was higher secretion of TGF-β, bFGF 
and PDGF when human tendon fibroblasts were 5% stretched at a frequency of 1 Hz 
47
. 
In contrast, immobilization of rabbit tendons have shown reduction of water, 
proteoglycans, and collagen crosslinks 
10
 and decrease in mechanical properties and total 
weight 
48
. Proliferation of fibroblast as well as synthesis and realignment of collagen 
fibrils could also be stimulated when cyclic tension was applied 
49
. Although the optimal 
magnitude, frequency, duration and type of mechanical stimulation still remain unclear, 
mechanotransduction of tendon has sparked a lot of interests among researchers. 
 
2.4 Osteotendinous and myotendinous junctions  
 
Other than tendon itself, its connection to the bone (osteotendinous junction) and to the 
muscle (myotendinous junction) are of clinical importance as well. Myotendinous 
junction is generally more defined with tendon fibers connected to the endomysium fibers 
whereas osteotendinous junctions are usually featured into four zones of increasing 
mechanical stiffness: tendon, fibrocartilage, mineralized fibrocartilage and bone 
50-52
. 
These junctions are always subjected to great mechanical stress during the movement, 
hence making these junctions vulnerable to acute or overuse injuries 
53
.  
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Figure 2.2: Schematic diagram of osteotendinous and myotendinous junctions 
 
To repair these regions, they are usually sutured back to their anchorage sites. However 
some reports indicated the poor quality of repairs, slow healing process and even failure 
in re-establishing the translational junctions, eventually leading to recurrent injury 
54-56
. 
To address these, numerous efforts have been done, such as applying growth factors 
57,58
, 
improving suturing techniques 
59
, employing stem cells 
1
 or multi-lineage cells on 
biomimetic scaffolds 
60-63
, and promising results have been demonstrated. 
 
 
Although different approaches have been employed in order to improve tendon healing, 
there is a need to combine several approaches together, in order to better tackle on the 
issues which might hinder the tendon regeneration. Hence in this dissertation, we have 
utilized ―bench-to-bedside‖ approach by employing the knowledge obtained from clinical 
observance and applying engineering approach to create a sustained dual-drug therapy to 
address the issues in tendon TE. 
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 Chapter 3  
 
Experimental Methodology 
 
This chapter summarizes the materials and methodologies used in this work. 
First section reveals the materials used, followed by the fabrication of 
different types of drug-loaded scaffolds in second section. In vitro drug 
release studies were then described in third section and the scaffolds were 
characterized as described in fourth section. The resulting scaffolds were 
then subjected to cell studies in fifth section and being evaluated for their 
efficacy in inducing relevant cellular responses in sixth section. Statistical 
analysis was done whenever necessary in this work to demonstrate whether 
there were significant differences among and between groups of specimens. 
The methods used for statistical analysis were described in the last section.  
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3.1 Materials selection 
 
Biodegradable polymers such as poly (L-lactic acid) (PLLA; intrinsic viscosity=6.5 dL/g; 
Purac Biomaterials), poly (lactic-co-glycolic acid, 80:20) (PLGA, Evonik Industries, 
intrinsic viscosity= 1.7 - 2.6 dL/g), poly (ε-caprolactone) (PCL; MW=70 000–90 000; 
Sigma Aldrich), which are FDA approved, were used as received.  
 
3.2 Materials fabrication 
 
In view of the different requirements while incorporating different therapeutic agents, two 
types of electrospun scaffolds were fabricated. 
 
3.2.1 Preparation of electrospinning solutions 
 
3.2.1.1 Solutions for NPS scaffold 
 
To address the adhesion formation issue, PLLA and PCL were used as the materials for 
scaffolds fabrication. Electrospinning solutions were prepared at a total polymer 
concentration of 8w/v% PLLA–PCL blends with 0.4 w/v% naproxen sodium (NPS, 
Sigma Aldrich) (relative to 1,1,1,3,3,3-hexafluoro-2-propanol, HFIP, Sigma Aldrich). 
Solutions with varying PLLA:PCL ratio (i.e. 70:30, 80:20 and 90:10) was prepared to 
understand the effect of polymer compositions. Subsequently, 3%, 5%, 7% and 10% v/v 
deionized water was added into HFIP to investigate the effect of co-solvent (i.e. water). 
Scaffolds were named according to their PLLA ratio, followed by PCL ratio and its 
percentage water volume. For example, 90-10-3 indicates 90wt% PLLA blended with 
10wt % PCL, coupled with 3% (v/v) water in HFIP. 
 
3.2.1.2 Solutions for IGF-1 scaffold 
 
For the fabrication of insulin-like growth factor 1 (IGF-1, Sigma Aldrich) scaffolds, 
PLGA and PCL were used instead. 8w/v% of PLGA-PCL blends (relative to HFIP) with 
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different ratios (i.e. 70:30 and 80:20) were prepared to understand the effect of polymer 
compositions on IGF-1 release. 5wt% of poly (ethylene oxide) (PEO, Mv = 4 X 10
6
 Da, 
Sigma Aldrich) (relative to total polymer mass) was added to facilitate the IGF-1 release. 
In addition, different concentrations (i.e. 8w/v%, 5w/v% and 3w/v%) of PLGA-PCL 
blends at the ratio of 70:30 (with PEO) were also prepared to obtain different release 
profiles. Scaffolds were named according to their concentration, followed by PLGA-PCL 
ratio and whether with or without PEO in the formulations. For example, 8-70/30-0 
indicates 8 w/v% of polymer with the composition of 70wt% PLGA blended with 30wt % 
PCL, and 0 wt% of PEO in the formulation. 
 
3.2.2 Fabrication of electrospun scaffolds 
 
Electrospinning is a fiber production method which uses electric force to draw polymer 
jets into nano to micron range fibers 
1
. Electrospinning was performed to fabricate 
scaffolds by using the MECC Nanon-01A Electrospinning Set-up. A single-nozzle 
spinneret (22 gauges) was used and different solutions were dispensed at an accelerating 
voltage of 15 kV and constant feed rate of 1 mL/h. To obtain scaffolds with aligned 
morphology, fibers were electrospun and collected by using a metallic mandrel set-up, 
which was rotated at 1500 rpm and fixed at 14cm away from the tip of the spinneret.  
 
For combined scaffolds, NPS electrospinning solution was electrospun under the 
aforementioned conditions then followed by electrospinning of equal amount of either 
IGF-1 containing or pure PLGA/PCL/PEO solutions (empty scaffolds) to obtain IGf-1 
scaffold + NPS scaffold or Empty scaffold + NPS scaffold respectively. 
 
Figure 3.1: Schematic diagram of the multi-layered scaffolds which release IGF-1 and NPS. 
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3.3 In vitro drug release studies 
 
Scaffolds were weighed accurately in triplicate, placed in vials containing 5mL 
phosphate-buffered saline (PBS; pH7.4; OHME Scientific) and incubated in a shaking 
incubator at 37°C. PBS, which possesses a physiologically relevant concentration of ions 
similar to the human body, was used in the study. 
 
3.3.1 Release of naproxen sodium (NPS) 
 
At predetermined time intervals, 1 mL PBS solution was removed completely and 
replenished with fresh PBS solution from each vial. The concentration of released NPS 
was analyzed using a Shimadzu UV-2501 ultraviolet–visible (UV-vis) spectrophotometer 
at 331nm. A UV-vis spectrophotometer can be used for quantitative determination of 
different analytes. Briefly, a monochromatic beam passes through a cuvette containing a 
solution of the samples. Through absorbing energy in the form of visible light or 
ultraviolet, sample molecules which contain non-bonding electrons (n-electrons) or π-
electrons excite their electrons to higher anti-bonding molecular orbitals, resulting in light 
absorption and the intensity of the sample beam is defined as I. The intensity of the 
reference beam, which passes through the cuvette containing only the solvent, is defined 
as I0. Absorbance (A) is defined as log I0/I. The molar concentration of the sample (c) 
could be calculated from the formula, c = A / ε l (where A= absorbance, ε = molar 
attenuation coefficient of the sample and  l = length of light path through the cuvette) 
2
.  
 
3.3.2 Release of insulin-like growth factor 1 (IGF-1) 
 
Released medium (in PBS) was removed completely daily and replenished with fresh 
PBS solution. The released IGF-1 amount was characterized by using IGF-1 ELISA Kit 
(Abcam). ELISA (enzyme-linked immunosorbent assay) is a technique that uses 
antibodies and color change to identify and quantify the amount of a substance 
3
. Briefly, 
released IGF-1 was absorbed to a pre-coated surface. Then, IGF-1 specific biotinylated 
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detection antibody was applied over the surface so it can bind to the attached IGF-1. This 
antibody was linked to Streptavidin-Peroxidase Conjugate, and, in the final step, TMB 
was added to visualize Streptavidin-Peroxidase enzymatic reaction. The concentration of 
IGF-1 could be determined by measuring the absorbance using Infinite200 microplate 
reader (Tecan Inc) at wavelength of 450 nm. 
 
The total IGF-1 amount inside the polymers was quantified by using microBCA assay 
(Thermo Fisher Scientific). It is a biochemical assay for determining the total 
concentration of protein in a solution (in the range of 0.5µg/mL to 20µg/mL) 
4
. The IGF-
1 scaffolds were firstly weighed and then being degraded in 1M NaOH for 2 weeks. Once 
scaffolds degraded, solutions were diluted 10 times in PBS to yield concentration at 0.1M 
NaOH and mixed with equal amount of microBCA working solution (through mixing the 
reagent A, reagent B and reagent C at ratio of 25:24:1) and underwent incubation at 37°C 
for two hours, prior to the measurement of the absorbance at 562nm. The background 
readings (the values of empty scaffolds) were deducted and the amounts of IGF-1 were 
obtained from the plot of the calibration curve. 
 
3.3.3 Determination of IGF-1 stability in different solvents 
 
Same amount of IGF-1 solution (reconstituted in water) was added into different solvents, 
namely dichloromethane (DCM, Tedia), HFIP, water and HFIP + PEO. The solutions 
were mixed and stirred for 30 min then being freeze-dried. The freeze-dried samples were 
then reconstituted in ELISA buffer and checked for their concentration. Control was the 
freshly prepared IGF-1 solution, which was set at 100% stability. 
 
3.4 Materials Characterization 
 
3.4.1 Morphological assessment of electrospun scaffolds 
 
The microstructures of the prepared scaffolds were observed under a field emission 
scanning electron microscopy (FESEM; JSM-6340F, Jeol Co.). In principle, FESEM 
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scans a sample with a focused beam of electrons, producing secondary electrons from the 
sample which are detected by the detector and to give out information such as surface 
topography and composition 
5
. The scaffolds were sputtered with platinum for 60s at 
20mA and analyzed at an accelerating voltage of 5 kV. A total of 50 independent fibers 
were used to determine the mean fiber diameter using ImageJ software (n=50). 
 
3.4.2 Contact angle and wetting tension 
 
Contact angle could provide information about the wettability of a solid surface by a 
liquid 
6
. A static sessile drop technique was utilized to evaluate the contact angles of the 
scaffolds on a contact angle goniometer. Distilled water was pumped out at a rate of 5 
μL/s onto the scaffolds and the droplet was allowed to relax for 10 s prior to taking the 
images for analysis using FTA32 software. The measurements were conducted at room 
temperature in triplicate. 
 
3.4.3 Surface properties of electrospun NPS scaffolds 
 
X-ray photon spectrometry (XPS) was utilized to determine the distribution of NPS 
within the electrospun fibers. XPS analyzes the number and kinetic energy of the 
electrons escape from the top 10nm of the materials after being irradiated with a beam of 
X-rays 
7
. Kratos AXIS UltraDLD spectrometer (Kratos Analytical Ltd) with a mono Al 
Kα radiation source (hν=1486.71 eV) was performed at 5mA and 15 kV (n=3) to give out 
the information regarding the surface properties of the NPS scaffolds. 
 
3.4.4  Mechanical properties of electrospun scaffolds 
 
Tensile testing was performed on Instron tensile machine 5567 to measure the mechanical 
properties of the scaffolds. A load cell of 500 N with a load generation of 5mm/min was 
used to pull the scaffolds which were cut into a standard dumbbell shape (according to 
ASTM D 638-08) and tested at room temperature. Three samples for each formulation 
were used to calculate tensile strength (σ), strain at break (ϵ) and Young‘s modulus (E) of 
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the scaffolds (n=3). Generally, the tensile strength of a material is the maximum amount 
of tensile stress that it can take before failure 
8
. The Young‘s modulus was determined by 
calculating the gradient of the initial linear slope of the stress-strain curve 
9
. Elongation at 
break is the ratio between initial length and changed length after the test sample breaks. It 
indicates the ability of a material to resist shape changes without crack generation 
10
. 
 
3.4.5 Hydrolytic degradation of electrospun scaffolds 
 
Three samples (1×1 cm
2
) from each formulation were first weighed (W0) before PBS 
incubation at 37°C. At fixed time points, the electrospun scaffolds were washed with 
deionized water and excess water were blotted off prior to measurement of the wet 
weight (Wwet) (n=3). The samples were then thoroughly dried in a vacuum oven for at 
least 1 week before measuring the dry mass (Wdry) gravimetrically. The water uptake was 
determined according to the following equation: 
 
Water uptake (%) =  [(Wwet – Wdry) / Wdry] X 100% 
 
These samples were then dissolved in 1 mL of chloroform for at least an hour and filtered 
through 0.2 μm cellulose filters into vials and immediately capped for size exclusion 
chromatography analysis. Size-exclusion chromatography (SEC) is a technique which 
separates molecules according to their size molecular weight 
11
and information about the 
molecular weight change could be obtained accordingly. 
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3.5 Cell Studies 
 
3.5.1 Cell culture 
 
Four types of cells have been utilized in the work:  
 
3.5.1.1 L929 on NPS scaffold 
 
L929 murine fibroblasts have been utilized to evaluate NPS loaded aligned scaffolds‘ 
biocompatibility. L929 murine fibroblasts (CCL-1
TM
; ATCC) were cultured in Dulbecco‘s 
modified Eagle‘s medium (DMEM; PAA Laboratory) with 10% fetal bovine serum (FBS; 
PAA Laboratory), 1% L-glutamine (200mM; PAA Laboratory) and 1% penicillin–
streptomycin (Gibco) at 5% CO2 and 37°C. Scaffolds were cut into circular discs of 
2.15cm diameter, sterilized for 30 min with UV and washed three times with PBS. Cells 
were then seeded at a density of 5000 cells/cm
2
 onto the samples. The samples were 
subsequently incubated for 3 h to allow cell attachment at 37°C and 5% CO2. Afterwhich, 
1 mL complete culture medium was added into each well. Tissue culture polystyrene 
(TCPS) was used as the control. The medium was replenished every 3 days. 
 
3.5.1.2 C2C12 on IGF-1 scaffold 
 
C2C12 murine skeletal myoblasts (Sigma) were cultured in Dulbecco‘s modified Eagle‘s 
medium (DMEM; PAA Laboratory) with 20% fetal bovine serum (FBS; PAA Laboratory) 
and 1% penicillin–streptomycin (Gibco) at 5% CO2 and 37°C. Scaffolds were cut into 
1cm x 1cm square shapes, sterilized for 30 min with UV and washed three times with 
PBS. Cells were then seeded at a density of 100000 cells/cm
2
 onto the samples. The 
samples were subsequently incubated for 3 h to allow cell attachment at 37°C and 5% 
CO2. Afterwhich, 1 mL complete culture medium was added into each well. Empty 
scaffolds were used as the control. The medium was replenished every 3 days. Once the 
cells become confluent, the growth medium was changed into differentiation medium 
which consisted of DMEM supplemented with 2% horse serum (Sigma) and 1% 
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penicillin–streptomycin (Gibco).  
 
3.5.1.3 Tenocytes on IGF-1 scaffold 
 
Tenocytes (ZenBio inc.) were cultured not more than passage 4 in the Tenocyte Culture 
Medium (ZenBio inc.) which composed of FBS and Penicillin / Streptomycin / 
Amphotericin B at 37°C and 5% CO2. IGF-1 scaffolds were cut into 1cm x 1cm square 
shapes, sterilized for 30 min with UV and washed three times with PBS. Cells were then 
seeded at a density of 50000 cells/cm
2
 onto the samples. The samples were subsequently 
incubated for 3 h to allow cell attachment at 37°C and 5% CO2. Afterwhich, 1 mL 
complete culture medium was added into each well. Empty scaffolds were used as the 
control. The medium was replenished every 3 days. 
 
3.5.1.4 TE85 on IGF-1 scaffold 
 
TE85 human osteosarcoma (Sigma) were grown in culture medium of Minimum 
Essential Medium (MEM, Gibco), 10% FBS (FBS; PAA Laboratory), 1% L-glutamine 
(200mM; PAA Laboratory) and 1% penicillin–streptomycin (Gibco) at 37°C and 5% CO2. 
Scaffolds were cut into 1cm x 1cm square shapes, sterilized for 30 min with UV and 
washed three times with PBS. Cells were then seeded at a density of 100000 cells/cm
2
 
onto the samples. The samples were subsequently incubated for 3 h to allow cell 
attachment at 37°C and 5% CO2. Afterwhich, 1 mL complete culture medium was added 
into each well. Empty scaffolds were used as the control. The medium was replenished 
every 3 days. Once the cells become confluent, the growth medium was changed into 
differentiation medium which consisted of DMEM (Gibco), 10% FBS (PAA Lab), 1% 
penicillin–streptomycin (Gibco), 10 mM β-Glycerol phosphate disodium salt 
pentahydrate (β-Gly, Sigma), 0.05mM L-Ascorbic acid 2-phosphate sesquimagnesium 
salt hydrate (ASB, Sigma) and 0.1µM dexamethasone (DEX, Sigma). 
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3.5.1.5 Tri-culture of C2C12/Tenocytes/TE85 on IGF-1 scaffolds 
 
 
Figure 3.2: Schematic diagram of the set-up for tri-culture experiments, where two 12mm coverslip acted 
as separator to prevent cells mixing during seeding on IGF-1 scaffolds. 
 
IGF-1 scaffolds were cut into 5 cm x 1cm rectangular shapes sterilized for 30 min with 
UV and washed three times with PBS. Prior to the cells seeding, two pieces of 12mm 
coverslips were placed on top of the scaffolds as the separators to facilitate the seeding of 
different cell types, as illustrated in Scheme 3.1. Three types of cells, include TE85, 
tenocytes and C2C12, were then seeded in the uncovered regions, without mixing, 
respectively. The cell-seeded samples were incubated for 3 h at 37°C and 5% CO2 to 
allow cell attachment in petri dish. Subsequently, each well was filled with 5 mL culture 
medium which consisted of DMEM (Gibco) supplemented with 20% FBS (PAA 
Laboratory) and 1% penicillin–streptomycin (Gibco). The medium was changed to 
differentiation medium which consisted of DMEM (Gibco), 2% horse serum (Sigma) and 
1% penicillin–streptomycin (Gibco), 10 mM β-Glycerol phosphate disodium salt 
pentahydrate (β-Gly, Sigma), 0.05mM L-Ascorbic acid 2-phosphate sesquimagnesium 
salt hydrate (ASB, Sigma) and 0.1µM dexamethasone (DEX, Sigma) after culturing for 3 
days. 
 
3.5.2 Cell quantification 
 
3.5.2.1  PicoGreen assay 
 
Cells were lysed with 0.25% trypsin and 0.1% Triton X-100 at predetermined time points. 
Cell lysates were mixed with equal amount of PicoGreen working solution. PicoGreen 
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(Invitrogen) has been commonly used to quantify the amount of double stranded 
deoxyribonucleic acid present within the cells. The fluorescence detected at the excitation 
and emission wavelengths of 480nm and 520nm respectively, which directly indicates the 
cells number and tells the information regarding the proliferation of the cells 
12
. 
 
3.5.2.2  AlamarBlue assay 
 
The principle of AlamarBlue is through measuring the reduction of resazurin, active 
ingredient of AlamarBlue reagent, to resorufin by the viable cells and this could tell the 
information about the cell metabolism 
13
. To measure the metabolic activity, cell culture 
medium was changed to DMEM without phenol red (Gibco) supplemented with 10% 
AlamarBlue reagent. The cells were incubated in the dark at 37°C and 5% CO2 for 4 h 
before the medium was checked for the absorbance at wavelengths of 570nm and 600nm.  
 
3.5.3 Cell morphology analysis 
 
Live/Dead staining assay has been employed to measure the cell viability and distribution. 
Samples were washed with PBS and incubated in a solution of 4 μM ethidium 
homodimer-1 (Invitrogen) and 2 μM Calcein-AM (Invitrogen) for 15 min at 37 ºC. 
Samples were then washed with PBS and observed under a fluorescence microscope 
(Nikon 80i) at10x magnification. 
 
3.5.4 Immunocytochemistry 
 
Immunocytochemistry was conducted to visualize the cell morphology, internal 
microstructure or to indicate the differentiation tendency. Briefly, cells were fixed using 4% 
paraformaldehyde in PBS at room temperature for 15 min and permeabilized with 0.1% 
TritonX-100 in PBS at room temperature for 5 min. Subsequently, blocking of samples 
was done by adding 10% goat serum (Dako) in PBS for 1 h at room temperature, 
followed by incubation of primary antibody solution for overnight at 4°C. The primary 
antibody solutions were prepared by diluting mouse monoclonal anti-desmin antibody 
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(1:400, Sigma), rabbit polyclonal anti-RUNX2 antibody (1:50, Santa Cruz) in blocking 
solution for detection of desmin and RUNX2 respectively. Detection of primary 
antibodies were done by incubation of goat anti mouse Alexa Fluor 546 (1:400, 
Invitrogen) and goat anti rabbit Alexa Fluor 488 (1:400, Invitrogen) in blocking solution 
for 1h at room temperature, respectively. Cells cytoskeleton was visualized through the 
staining of phalloidin (1;400, Invitrogen) in PBS for 1 h at room temperature. The nuclei 
were counterstained by DAPI (1:1000, Invitrogen) at room temperature for 5 min. 
Samples were washed with PBST (PBS with 0.05% tween 20) thrice after every 
incubation step. Finally, samples were transferred onto glass coverslips and mounted with 
fluorescent mounting medium (Dako) for taking images under a fluorescence microscope 
(Nikon 80i) at 10x magnification. Negative staining (without secondary antibody) was 
done to confirm the signal obtained was not non-specific staining 
 
3.5.5 Western blotting for determination of IGF-1 bioactivity 
 
To determine the bioactivity of encapsulated IGF-1, IGF-1 scaffolds were soaked into 
culture medium for 1 day and 7 days under 37°C and 5% CO2. The conditioned mediums 
were then added into wells with confluent C2C12 cells and treated the cells for 30 min 
prior to cell lysis.  
 
Cells were lysed in a 10:1 (v:w) ratio of ice-cold buffer containing 50 mM Tris-HCl (pH 
7.4), 0.5% sodium deoxycholate, 150mM sodium chloride, 0.5 mM EDTA, 1% NP-40, 1% 
SDS and protease inhibitor cocktail (100X). Cell lysates were then centrifuged at 13 000g 
at 4ºC for 10 min and subsequently the protein concentration was determined by using 
Bradford Assay (Bio-Rad). 5 μg proteins were then loaded into 10% acrylamide gels and 
electrophoresis was conducted at 100 V for 20 min and then at 200 V for 40 min. After 
transferring the proteins to polyvinylidene diflouride (PVDF) membranes, 5% non-fat 
milk powder in Tris Buffered Saline with 0.05% Tween (TBS-T) was used for the 
blocking process. After 1 h of blocking, primary antibodies from Cell Signaling 
Technology such as Phospho-Akt Ser473 antibody (no. 9271), total Akt antibody (no. 
9272) and β-Actin antibody (no. 4967) were used to stain the membranes at 4ºC 
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overnight. The PVDF membranes were then washed thrice prior to the incubation of 
secondary antibody, horseradish peroxidase-linked anti-rabbit immunoglobulin G (no. 
7072; New England Biolabs), at room temperature for 1 h. The membranes were then 
washed thrice and exposed to chemiluminescence detection reagent (RPN 2106; 
Amersham Biosciences). The membranes were scanned using Molecular Imager® 
ChemiDoc™ XRS System (Bio-Rad) and the blot density was determined by using 
Quantity One 1-D Analysis software (Bio-Rad). 
 
3.5.6 Real time quantitative polymerase chain reaction  
 
Real time quantitative polymerase chain reaction (qPCR) was used to determine 
expression of specific mRNA levels on the constructs. qPCR uses the DNA amplification 
concept to amplify a certain sequence and determine the expression of certain genes 
14
. 
Primer sequences (see Table 3.1), were checked for specificity by performing BLAST 
searches (http://blast.ncbi.nlm.nih.gov/Blast.cgi), and melt curve analysis. All primers 
were ideally designed to span exon-exon boundaries to prevent amplification of genomic 
DNA and with 40-60% GC content. RNA was isolated using TRIzol (Sigma) according to 
manufacturer‘s instructions and then re-suspended in RNA storage solution (Sigma).  
 
To conduct qPCR, Applied Biosystems 7300 Real Time PCR System and the associated 
sequence detection software (Version 1.4) was employed. SYBR Green gene expression 
assays and PCR mastermixes (Applied Biosystems) were used to evaluate the expression 
of the endogenous control (RPIIβ) and the target genes. Fluorescence was detected after 
every cycle and data was analyzed using the 2 
(-ΔΔCT) method using RPIIβ as a 
housekeeping gene. ΔCT 1 corresponds to the difference in CT between target genes and 
endogenous control, and ΔCT 2 corresponds to the difference in CT between target genes 
and endogenous control in the calibrating samples. 
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Table 3.1: Primers used for the differentiation determination 
Gene target Sequence (5’-3’) 
Scleraxis F: CAGCGGCACACGGCGAAC 
R: CGTTGCCCAGGTGCGAGATG 
Tenomodulin F: CCATGCTGGATGAGAGAGGTT 
 R: TTGGTAGCAGTATGGATATGGGT 
Collagen I α1 F: TAAAGGGTCACCGTGGCT 
 R: CGAACCACATTGGCATCA 
RUNX2 F: TGGTTACTGTCATGGCGGGTA 
 R: TCTCAGATCGTTGAACCTTGCTA 
Myogenin F: GCAGGCTCAAGAAAGTGAATGA 
 R: TAGGCGCTCAATGTACTGGAT 
RPIIβ F: ACATAACGAAGACGGTCAT 
 R: TAAGCCATTCAACAAGCAATA 
 
3.5.7 Assessment of mineralization by Alizarin Red S staining 
 
Calcium deposition is commonly used to indicate osteogenesis was determined by using 
Alizarin Red S staining 
15
. Briefly, constructs were rinsed with PBS (without Ca
2+
) thrice 
and fixed with 4% paraformaldehyde in PBS for 15 min. 10% ammonium hydroxide was 
used to adjust the pH of 2% (w/v) Alizarin Red S (Sigma) in distilled water to 4.2. The 
constructs were stained for 15 min and followed by thorough washing before being 
imaged digitally or using optical microscopy at 10x magnification. 
 
3.6  Statistical analysis 
 
One-way analysis of variance (ANOVA), followed by Tukey‘s HSD post hoc test, on 
SPSS v. 11.5 software were conducted to compare between different groups. One-way 
ANOVA is a statistical technique used to determine if the means are different between 
samples (using F distribution). If the variance between groups is larger than the variance 
within the group, it's likely that the mean differs 
16
. Tukey's HSD post hoc test is a 
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statistical test for executing all pairwise comparisons. It is fundamentally similar to t-test, 
with the correction of type I error when multiple comparisons are made. For conducting 
Tukey's test, the groups should be normally distributed, independent and the within-group 
variance should be equal 
17
. Differences were considered statistically significant at p < 
0.05. 
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Chapter 4  
 
Sustained-release of Naproxen Sodium from Electrospun-
aligned PLLA–PCL Scaffolds 
 
The unfavorable adhesion formations, due to the inflammation response 
after surgery, restrict the tendon healing. It has been demonstrated that NPS 
can inhibit inflammatory response and hence prevent adhesion formation. 
Thus, this work aims to incorporate a non-steroidal anti-inflammatory drug, 
naproxen sodium (NPS) into aligned electrospun scaffolds to address this 
issue. Factors such as polymer composition (i.e. poly-L-lactic acid (PLLA): 
poly (ε-caprolactone) (PCL) ratios) and solvent composition (i.e. 
hexafluoroisopropanol:water ratios) were explored to gain knowledge on 
how these factors can affect NPS release from electrospun scaffolds and thus 
be optimized to achieve NPS sustained release. Results showed that NPS 
could be released sustainably for as long as 2 weeks by changing the amount 
of water as the co-solvent. Besides, scaffold breaking strength increased with 
the addition of water as the co-solvent. Tenocytes cultured on the NPS 
scaffolds adhered well to the scaffolds and exhibited their typical elongated 
morphology. Besides, tenocytes could respond to the topographical cues 
given by the aligned fibrous scaffolds, creating a network of cells which 
mimic the native tendon tissue arrangement. These scaffolds are therefore 
potential candidates in enhancing tendon regeneration in vivo due to their 
desirable tendon TE characteristics. 
.
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4.1 Introduction 
 
It has been reported that there are approximately 15 million musculoskeletal injuries 
relating to the impairment of ligament and tendon annually 
1
. Due to the low vascularity 
and cellularity of these organs especially for tendon 
2
, unaided natural healing usually 
results in deteriorated tissue functionality 
3
. Tissue engineering (TE) thus came forth as a 
potential field that helps to provide viable solutions to tendon tissue regeneration. 
Enormous efforts were done with the aim to mimic the tendon microenvironment through 
investigating different materials as the scaffold 
4-9
, selecting appropriate cell types 
9,10
 and 
evoking the healing of tendon tissues, either chemically 
11-13
 or mechanically 
14-17
. 
Although promising results were demonstrated through TE approach, the problem of 
post-surgical adhesion formation, which might ultimately impede the success of tendon 
regeneration, is still insufficiently addressed. 
 
Adhesion formation, which is the abnormal adherence of the undesirable fibrous tissue to 
the surrounding structures, could happen as a result of huge inflammatory feedback at the 
surgical site 
18
. During the natural tendon-healing process, to recover the continuity of 
damaged tendon fibrils, collagen will be secreted 
19
. However, inflammatory cells will 
also be recruited to the injury site at the same time. The unfavorable integration of these 
inflammatory cells with the formed collagen fibrils results in scar tissue formations and 
adherence to the surrounding tissues. Such kind of adherence could interfere with the 
tendon gliding function and ultimately lead to recurrent injury 
3
. To reduce these 
peritendinous adhesions, numerous efforts have been attempted. For example, improving 
on the surgical techniques 
20
, tendon sheath closure 
21
 and post-operative mobilization 
22-
24
. Besides, researchers have also utilized materials such as hyaluronic acid 
16
, 
polyethylene tubes 
25
, silastic 
26
 and hydroxyapatite 
27
 to serve as a confinement between 
the repaired tendon and its surrounding tissues in a form of pseudo-sheath to address the 
adhesion formation issue. Nevertheless, certain extent of adhesion tissue formation was 
still observed  in the later phases of the experiments 
28
.  
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Another approach in preventing adhesion formation would be the prescription of 
nonsteroidal anti-inflammatory drugs (NSAIDs), in particular naproxen sodium (NPS). 
NPS is commonly prescribed to relieve pain and treat inflammation. Through the 
mechanism of decreasing the by-products of arachidonic acid and metabolites via 
competitive inhibition of cyclo-oxygenase, NPS can effectively reduce adhesion 
formation 
29,30
. However, the side effects of NPS include nausea, diarrhea and abdominal 
pain if administrating orally 
31
. In view of this, it is essential to design a system that can 
release NPS sustainably and locally so as to  minimize adhesion formation and at the 
same time avoid the systemic body response during tendon healing. Currently, direct 
compressing technique 
32
 and the use of hydrophilic matrices 
33
 have been employed to 
for the development of NPS-loaded products. However, drawbacks, such as rapid release 
of NPS from the hydrophilic matrices and inadequate mechanical properties 
34,35
, have 
limited their application in clinical practices. Existing studies that reported the release of 
NPS from hydrophobic matrices 
36-38
 yielded little successful, mainly because of the  low 
molecular weight and hydrophilicity of NPS. Therefore, this chapter will address the 
adhesion formation issue in tendon TE by designing a scaffold that is capable of 
releasing NPS sustainably and able to provide aligned bio-mimicking environment 
at the same time. It is postulated that the distribution of NPS in the electrospun fibers, 
and thus its release, can be controlled by manipulating the formulations of the 
electrospinning solution, i.e. co-solvent ratios and polymer ratios. These scaffolds, 
electrospun from different formulations, were evaluated and characterized in terms of 
their surface morphology, mechanical behavior, in vitro drug-releasing properties and cell 
compliance. 
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4.2 Materials and Methods 
 
For the information regarding the materials and methodology used in this chapter, please 
refer to Chapter 3. 
 
Table 4.1: Methods used in Chapter 4 
Description Section 
Scaffold fabrication Solution preparation 3.2.1.1 
Electrospinning process 3.2.2 
In vitro drug release 3.3.1 
Materials 
characterizations 
Scaffold morphology 3.4.1 
Scaffold hydropholicity 3.4.2 
Surface properties 3.4.3 
Mechanical properties 3.4.4 
Cell studies Cell seeding 3.5.1 
Cell proliferation 3.6.2.1 
Cell morphology 3.6.3 / 3.6.4 
 
 
4.3 Results 
 
Different ratios of 8 w/v% PLLA/PCL blends (90:10; 80:20; 70:30), together with 0.4 
w/v% NPS, were dissolved into HFIP and electrospun to look into the effects of polymer 
compositions on the drug releasing and structural properties. PLLA/PCL blend with ratio 
of 90:10 was then used to investigate the co-solvent (i.e. H2O) effect of HFIP/H2O 
solvent systems. For the co-solvent effect study, the scaffolds were prepared by adding 
0%, 3%, 5%, 7% and 10% of H2O into HFIP. Scaffolds were labelled with reference to 
their PLLA ratio, followed by PCL ratio and the water volume percentage. For example, 
90-10-3 indicated 90 wt% of PLLA blended with 10 wt% PCL, coupled with 3 % of H2O 
in HFIP (shown in Table 4.2). 
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Table 4.2: Description of different formulations of electrospinning solutions. 
 
 
4.3.1 Aligned fibrous scaffolds to mimic tendon micro-environment 
 
FESEM was conducted to observe the morphology of the scaffolds. All formulations of 
the electrospinning solution (with or without NPS) could be electrospun into well-formed 
microstructure of aligned fibers with negligible beads, as shown in Figure 4.1. Figure 
4.2A shows that changing the PLLA and PCL ratio has no significant effect in terms of 
fibers diameter. All the formulations yielded fibers with submicron range diameter: 1.071 
± 0.153 µm, 1.090 ± 0.233 µm and 0.944 ± 0.096 µm for 90-10-0 80-20-0 and 70-30-0 
respectively.  
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Figure 4.1: Aligned fibers with beadless morphology was obtained from varying formulations of 
electrospinning solutions with A) no NPS; and with NPS, (B) 70-30-0 (C) 80-20-0 (D) 90-10-0; (E) 90-10-
3; (F) 90-10-5; G) 90-10-7; H) 90-10-10. (scale bar = 10µm) 
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With regards to the co-solvent effects, as shown in Figure 4.2B, there is a decreasing 
trend of the fibers diameter with the addition of water. The average fibers diameter 
decreases (1.071 ± 0.153 µm > 0.995 ± 0.221 µm > 0.954 ± 0.197 µm > 0.836 ± 0.171 
µm > 0.760 ± 0.176 µm) while increasing water content from 0%, 3%, 5%, 7% to 10%. 
 
 
 
 
Figure 4.2: Graphs showing the difference in fibers diameter when changing (A) polymer composition, i.e. 
PCL to PLLA ratio, and (B) co-solvent composition, i.e. H2O to HFIP. When changing PCL percentage, 
there was no difference in fibers diameter. Decreasing trend in fibers diameter was observed when 
increasing H2O percentage (* indicates p < 0.05 wrt 90-10-0; # indicates p < 0.05 wrt 90-10-3; ** indicates 
p < 0.05 wrt 90-10-5). 
A 
B 
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4.3.2 NPS released sustainably up to two weeks 
 
Figure 4.3A shows the in vitro NPS release profiles when different PCL to PLLA ratios 
were used. For the formulation of 90-10-0, the NPS release could be tremendously 
slowed down, with the first hour burst release recorded at about 25% and NPS released 
sustainably up to 3 days. However, relatively faster NPS release was observed on 80-20-0 
and 70-30-0 formulations, which can only last for1 day. 
 
Figure 4.3B shows the effect of co-solvent (i.e. H2O) on NPS. When 3% of H2O was 
added, there was a significant reduce of NPS release rate. Release of NPS could last for 
two weeks with low amount of NPS burst release. However, with the increasing of water 
content, it was found that release became faster, where formulation 90-10-5 could 
continue to release NPS for about ten days but 90-10-7 and 90-10-10 scaffolds could only 
release NPS for less than seven days. Throughout the experiment, the NPS spectrum was 
similar with the spectrum on the first day of release, indicating that there is no 
denaturation of the NPS. 
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Figure 4.3: Plots showing cumulative NPS release from the scaffolds with different: A) PLLA to PCL ratio 
and B) H2O to HFIP ratio. Scaffolds with higher PCL to PLLA ratio has contributed to faster release of 
NPS. The addition of 3 vol% H2O has resulted in scaffolds with slower NPS release profiles, which lasted 
for two weeks. However, further increasing H2O content yielded scaffolds with faster NPS release profiles.  
 
4.3.3 Scaffold hydrophilicities affected NPS release profiles 
 
Scaffolds‘ hydrophilicities, which have influence in affecting the associated release 
profiles, were determined by contact angle and water uptake measurements. Figure 4.4 
demonstrates the contact angle of various scaffolds. 90-10-0 scaffold showed lower 
hydrophilicity, as evidenced from the higher contact angle compared to that of 80-20-0 
and 70-30-0, as shown in Figure 4.4A. Figure 4.4B shows that the contact angle has no 
significant change when changing the amount of the H2O as the co-solvent. 
B 
A 
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Figure 4.4: Graphs showing the contact angle measurements of different scaffolds with varying: A) PCL to 
PLLA ratio and B) H2O to HFIP ratio. 70-30-0 and 80-20-0 scaffolds have significant lower contact angle 
than that of the 90-10-0. When varying the H2O to HFIP ratio, contact angle of the scaffolds did not 
significantly change. (* indicates p < 0.05) 
 
Figure 4.5 shows that water uptake measurements of different scaffolds after immersing 
in PBS for 7 days. As shown in Figure 4.5A, 90-10-0 scaffolds have significantly lower 
water uptake than that of 70-30-0 and 80-20-0 scaffolds (p < 0.05). Meanwhile the water 
uptake of the scaffolds has no difference while varying the percentage of H2O as co-
solvent (Figure 4.5B). 
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Figure 4.5: Graphs showing water uptake measurements of different scaffolds with varying A) PCL to 
PLLA ratio and B) H2O to HFIP ratio, after immersing in PBS for 7 days. Lower water uptake was 
observed for 90-10-0 scaffolds. While changing the percentage of H2O as co-solvent, no significant 
difference in water uptake was observed. (* indicates p < 0.05) 
 
4.3.4 Co-solvent affected NPS distribution inside the fibers 
 
X-ray photon spectrometry (XPS) has been employed to determine the presence of NPS 
at the binding energy of 1071 eV, which is the Na 4s characteristic peak. Figure 4.6 
demonstrates the XPS analysis of scaffolds with and without NPS. The presence of NPS 
on scaffold 90-10-10, 90-10-3 and 90-10-0 could be confirmed with the peak observed, 
 
A 
 
B 
* p < 0.05 
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while there was no peak detected on 90-10 (No NPS) scaffold at that particular region. 
The area under the spectra could be interpreted as the amount of NPS present on the 
surface of the fibers (depth of 0-10nm). Figure 4.6 shows that relatively lower NPS 
amount was detected on 90-10-3 scaffolds (Figure 4.6, dash-dot line). Whereas, when no 
water was added as the co-solvent (90-10-0, Figure 4.6, solid line), higher amount of NPS 
was detected, while. However, a spectrum with an intermediate area that lies between 90-
10-3 and 90-10-0 when increasing the percentage of co-solvent to 10 vol%. 
 
 
Figure 4.6: Plot showing the XPS analysis of the scaffolds with and without NPS. Na 4s characteristic peak 
indicates the presence of NPS on scaffold 90-10-10 (dotted line), 90-10-3 (dash-dot line) and 90-10-0 (solid 
line). There was no peak detected for scaffold without NPS (dash line) at that particular region. 
 
4.3.5 Scaffolds yielded optimal mechanical properties 
 
The mechanical properties of various fibrous scaffolds could be seen in Figure 4.7 and 
Table 4.3. Apparent Young‘s modulus (Eapp, Figure 7A solid line) and apparent tensile 
strength (σapp, Table 4.3) of the scaffolds were not significantly altered while changing 
the PLLA to PCL ratio, which were of average 300 MPa and 25 MPa respectively. 
However, as shown in Figure 6A (dotted line), the elasticity of the scaffolds has been 
improved with increasing the PCL to PLLA ratio. When more PCL was added, the 
apparent strain at break (ϵapp) improved: 70-30-0 ~ 80-20-0 > 90-10-0. 
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Figure 4.7: Plots showing mechanical properties of the scaffolds with varying: A) PLLA to PCL ratio and 
B) H2O to HFIP ratio. The apparent Young‘s modulus was similar for the scaffolds with different 
formulations. Lower PCL to PLLA ratio has yielded scaffolds with lower elasticity. Elasticity of the 
scaffolds increased with minimal amount of H2O (3 vol%), however it dropped with increasing H2O 
percentage. 
 
As shown in Figure 4.7B, the addition of the H2O did not significantly alter the σapp and 
Eapp of the scaffolds, which were on average 15 MPa and 250 MPa respectively. However, 
formulation 90-10-3 has resulted in the scaffolds with maximum ϵapp value, which was at 
51.29 ± 5.56 % as shown in Figure 7B (dotted line). 
 
 
A 
B 
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Table 4.3: Mean fiber diameter and mechanical properties of the scaffolds 
Samples  
Mean Fiber Diameter 
(µm) 
Apparent Young's 
Modulus (MPa) 
Apparent Tensile 
Strength (MPa) 
Apparent Strain 
at Break (%) 
70-30-0  0.944 ± 0.096  290.31 ± 31.36 24.99 ± 1.13 51.33 ± 6.06 
80-20-0  1.090 ± 0.233  325.03 ± 9.38 27.18 ± 0.39 60.69 ± 11.25 
90-10-0  1.071 ± 0.153  284.18 ± 28.58 20.04 ± 1.80 28.44 ± 9.87 
90-10-3 0.995 ± 0.221  224.41 ± 36.44 14.99 ± 2.70 51.29 ± 5.56 
90-10-5  0.954 ± 0.197  272.15 ± 8.38 18.87 ± 0.37 37.29 ± 3.03 
90-10-7  0.836 ± 0.171  244.37 ± 1.78 16.76 ± 1.01 28.51 ± 9.27 
90-10-10  0.760 ± 0.176  256.26 ± 26.77 14.57 ± 1.23 11.72 ± 7.34 
 
4.3.6 NPS scaffolds exhibited no cytotoxicity on L929 
 
According to ASTM standard (ASTM F813-07: Standard Practice for Direct Contact Cell 
Culture Evaluation of Materials for Medical Devices), cytotoxicity of the scaffolds were 
evaluated by assessing the L929 murine fibroblasts viability through using the Live/Dead 
staining assay on the NPS scaffold (90-10-3). Figure 4.8 shows the fluorescence images 
of L929 cultured samples. On day 1 of culture, viable cells were stained green on NPS 
scaffolds as well as TCPS, which served as the positive control. By day 7, cells on the 
NPS scaffolds arranged themselves according to the orientation of the scaffolds and 
exhibited high degree of spreading while the cells on TCPS were quite confluent and 
some were rounded. 
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Figure 4.8: Fluorescence microscopy images of cells on aligned scaffold proliferated and arranged 
themselves according to the fibers orientation by day 7. Calcein-AM was used to stain viable cells (green) 
while ethidium homodimer-1 was used to stain the nuclei of non-viable cells (red). (scale bar = 50µm) 
 
4.3.7 Tenocytes exhibited elongated morphology but proliferation was slightly 
inhibited under NPS influence 
 
Tenocytes were seeded onto NPS scaffolds (90-10-3) and their proliferation was 
evaluated by using PicoGreen Assay. As shown in Figure 4.9, under the influence of NPS, 
cells cultured on NPS scaffolds showed relatively slower proliferation rate compared to 
empty scaffold (same formulation but no NPS was added). Nevertheless, immunostained 
images on Figure 4.9 show that tenocytes cultured on both scaffolds exhibited their 
typical elongated morphology. 
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Figure 4.9: Graph showing proliferation of tenocytes on NPS scaffolds was slightly prohibited, compared 
to empty scaffolds where cells proliferated after 3 days of culture. (* indicates p <0.05) 
 
 
  
Figure 4.10: Immunostaining images showing more tenocytes were visualized on A) empty scaffolds than 
on B) NPS scaffolds, where tenocytes showed elongated morphology were immunolabeled with phalloidin 
(red) to show cytoskeleton of the cells and counterstained with DAPI (blue) to indicate nucleus. (scale bar 
= 50µm) 
  
A B 
* p < 0.05 
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4.4 Discussion 
 
In order to enhance the healing process of tendon, not only is it necessary to consider TE 
approach in which a biocompatible material suitable for tendon-related cells to grow and 
function can be implanted to the injury site, it is vital to also consider the solution to the 
issue of undesirable post-surgical adhesion formation during tendon healing. Sustained 
releasing of NPS has been identified as one of the promising solutions to prevent 
adhesion formation 
33,34
. In this preliminary work, the possibility to incorporate NPS into 
a TE scaffold and achieve sustained release of NPS was shown by exploring different 
formulations. These formulations fixed with 0.4 wt% NPS, were varied in their polymer 
compositions (PCL to PLLA ratio) and percentage compositions of H2O as the co-solvent 
in the main solvent HFIP. 
 
Foremost, a scaffold which mimics the tendon‘s extracellular matrix (ECM) was 
fabricated by using electrospinning as a technique to process a mixture of polymers, 
PLLA and PCL loaded with NPS. Tendon ECM possesses well aligned closely packed 
collagen fibers. Hence, there are numerous efforts in fabricating fibrous scaffolds with 
aligned morphology. For example, Yin et al. demonstrated that human tendon 
stem/progenitor cells (hTSPCs) exhibited tendency of tendongenesis when they were 
cultured on nanofibers with aligned morphology rather than random morphology 
7
. The 
aligned morphology is hence deemed as an essential criterion in producing scaffolds with 
biomimetic structural properties for tendon regeneration. Scaffolds with better fibers 
alignment could be obtained from electrospinning conducted on mandrel set up at higher 
speed (1500rpm) 
39
. Aligned NPS-loaded PLLA/PCL scaffolds were therefore 
successfully fabricated from all formulations of the electrospinning solutions. Other than 
fibers orientation, fibers diameter was also an important consideration in tendon TE as 
tendon cellular responses could be affected by the fibers diameter. In this study, fibers 
diameter of the scaffolds was similar when changing the PCL to PLLA ratio, though 
lower viscosities of the electrospinning solution were observed 
40
. However, there was a 
decreasing trend of the fibers diameter when increasing the co-solvent (i.e. H2O) 
percentage. This could be understood as lower actual concentration of polymer solutions 
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were being pushed out at the tip of the spinneret due to increasing H2O portions 
41
. 
Another reason could be that the dielectric constant of the HFIP/H2O solutions had 
increased with the addition of H2O (dielectric constant = 80) into HFIP (dielectric 
constant = 18.7) 
42,43
. Overall, the fibers diameter obtained from all formulations in this 
study ranged from 0.7 um to 1.1um. This submicron feature highlighted the potential of 
these scaffolds for tendon TE because cell proliferation as well as production of collagen 
was promoted as the cells cultured on scaffolds with smaller fibers 
44
. 
 
Although scaffolds with desirable tendon TE morphological properties were successfully 
fabricated, the major concern was still the drug release profiles of NPS to prevent 
adhesion formations as mentioned earlier. Several attempts in loading of NPS into 
Eudragit S-100 coated sodium alginate microspheres, PLGA microspheres, lipid-like 
carnauba wax microparticles and electrospun cellulose acetate were reported 
37,45,46
. 
However, short NPS release profiles was achieved from a few hours to few days because 
of NPS‘s hydrophilic nature and low molecular weight. This relatively short NPS release 
profile is not completely sufficient for tendon healing as the inflammation process which 
can cause adhesion formation may sometimes last for as long as two weeks. In this study, 
different formulations of electrospinning solutions, which involve variations in polymer 
compositions and H2O percentage in HFIP, were investigated on their effects in drug 
releasing properties. Undesirable increase in NPS release was observed with higher PCL 
to PLLA ratio of the fibers. This is because PCL chains during the drug release study are 
in a flexible rubbery and highly mobile state with sufficient free volume
47,48
. This would 
allow more NPS to be diffused towards the fibers surface and thus resulting in a 
relatively faster release. As for the variation of the H2O percentage in HFIP, it was found 
that to a desirable slow release of NPS was achieved when H2O was introduced at 3% 
into the formulation as a co-solvent. It is hypothesized that the formation of two different 
phases within the fiber was formed with the presence of H2O as co-solvent, due to a 
change in the solvent evaporation rate. HFIP evaporates faster than H2O during the 
electrospinning process and this might have led to the formation of polymer shells 
trapping the H2O phase within the fiber. Being hydrophilic in nature, NPS hence prefers 
to reside inside the fiber with the H2O phase. As evidenced in Figure 4.6, lower amount 
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of NPS was detected by XPS on the fiber surface when H2O was added in the formulation, 
indicating that there are more NPS resided in the core region of the fiber (Figure 4.10). 
 
Figure 4.11: Schematic showing possible NPS distribution within the fibers when increasing the H2O 
percentage as the co-solvent in formulations: A) when no water was added, there was an even distribution 
of the NPS inside the fibers; (B) with the presence of minimal amount of H2O, more NPS tend to stay 
inside the fibers; however, (C) further increase the percentage of H2O resulted in thinner fibers and there 
was more NPS on the surface of the fibers. 
 
However, when increasing the percentage of H2O in the electrospinning solutions, this 
effect would be countered. Fibers with smaller diameter would be produced when 
increasing the H2O content, due to higher stretching experienced by the fiber. A higher 
release rate was observed due to the higher surface area to volume ratio in thinner fibers 
49
. Overall, this NPS release study has identified that the formulations with the least PCL 
to PLLA ratio and minimal H2O content (up to 3%) as the co-solvent gave the most 
optimal NPS release profile. It is applaudable that this formulation could release NPS 
sustainably as long as two weeks which was considered the longest sustained release of 
NPS ever reported compared to other published studies which reported three days as the 
highest. This long term release of NPS could have sufficiently alleviated the 
inflammation symptoms which might sometimes last for two weeks. 
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The scaffolds were investigated further to understand its potential as a TE scaffold for 
tendon regeneration. A natural tendon exhibits a very high Young‘s modulus of about 1.2-
1.6 GPa 
50
. Adequate mechanical property is thus an important criterion for TE scaffolds 
especially those for tendon regeneration. Due to the high modulus of PLLA, it was 
considered as the candidate polymer in order to match the Young‘s modulus of a tendon. 
However, PLLA is very brittle and hence PCL was introduced into the formulations to 
improve the elasticity of the resulting scaffolds. This is because the crystallinity of PLLA 
could be disrupted with the addition of PCL and thus resulting in improved elasticity 
51
. 
Scaffolds fabricated from all formulations possessed relatively good mechanical 
properties ranging from 250 to 300 MPa and 15 to 25 MPa for their apparent Young‘s 
modulus (Eapp) and apparent tensile strength (σapp) respectively.  
 
To investigate the influence of co-solvent (i.e. H2O) on the mechanical properties of the 
resulting scaffolds, only formulations with 90:10 PLLA/PCL composition were chosen as 
they possessed the most optimal NPS release profile. Results showed that highest 
elasticity was exhibited on the scaffold when 3% H2O was used in the electrospinning 
solutions. This might be because of the formation of solvent mixtures with higher boiling 
point when there is minimal amount of H2O in HFIP, leading to higher degree of 
molecular orientation of the polymer chains within the fiber (Figure 4.11), and hence an 
enhancement of elasticity 
51,52
. However, when increasing the H2O content, scaffolds 
exhibited lower elasticity as a result of the highly stretched polymer chains 
53
. 
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Figure 4.12: Schematic showing possible changes in the polymer chains when increasing water percentage 
as the co-solvent in electrospinning solutions: (A) when no water was introduced, polymer chains have 
lower molecular orientation; (B) with the presence of small amount of H2O polymer chains have higher 
molecular orientation; (C) with further addition of H2O polymer chains were highly stretched. 
 
Last but not least, these scaffolds were also tested for their biocompatibility. Preliminary 
cell study on L929 indicated that scaffolds exhibited no cytotoxicity and they were able 
to proliferate healthily and arrange themselves according to the fiber orientation. Culture 
of tenocytes as depicted on Figure 4.10 also showed that the cells could respond to the 
orientation of the fibrous morphology, and adopting their typical elongated morphology, 
mimicking the actual tendon tissues. As less proliferation of tenocytes was observed on 
NPS scaffolds due to the inhibitory effect of NPS on tenocytes proliferation, this scaffold 
will be coupled with the growth factors (GFs) releasing scaffolds in the next chapter to 
further enhance its potential in promoting tendon healing. The integration of NPS 
scaffold with GFs scaffold for enhanced tendon regeneration will be discussed in the next 
chapter. 
  
Naproxen sodium release for tendon tissue regeneration Chapter 4 
62 
 
4.5 Summary 
 
In this chapter we have demonstrated the feasibility to load NPS, which is a kind of 
hydrophilic anti-inflammation drug, into electrospun PLLA/PCL scaffolds with 
continuous, beadless and aligned fibrous morphology. Different portions of PCL inside 
the fibers were found to have less effect in affecting fibers diameter, though faster NPS 
release rate and higher strain at break were observed with increasing PCL content. 
Through further adjusting the H2O percentage which served as the co-solvent in HFIP, 
NPS was released sustainably as long as 2 weeks in a scaffold which possessed optimal 
mechanical properties. In vitro cell studies have shown that tenocytes could survive, 
exhibiting their typical elongated morphology and arranging themselves according to the 
fibers orientation. Although lower proliferation rate was observed under the influence of 
NPS, this optimized scaffold shall be coupled with scaffold which possesses GFs 
releasing ability as discussed in the next chapter, in order to further enhance its potential 
in promoting tendon healing  
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Chapter 5  
 
Controlled release of IGF-1 from Electrospun Scaffolds 
Enhanced Tenocytes Proliferation and Differentiation 
 
Slow tendon healing is devastating. Growth factors (GFs) are prescribed for 
tendon repair but they degrade easily in vivo, thus necessitating the need for 
delivery vehicles to release them timely. In this chapter, 
hexafluoroisopropanol was used as electrospinning solvent for its capability 
in better preserving insulin-like growth factor 1 (IGF-1) stability. IGF-1 was 
subsequently loaded into electrospun poly (lactic-co-glycolic acid)/ poly (ε-
caprolactone) (PLGA/PCL) aligned scaffold. Through adjusting the polymer 
composition (i.e. PLGA:PCL ratio and inclusion of poly (ethylene oxide)) 
and concentration of the electrospinning solution, a 10-week release of IGF-
1 was achieved. The released IGF-1 showed preservation of bioactivity and 
they were able to trigger C2C12 downstream cellular response. Tenocytes 
cultured on the scaffolds adopted their typical elongated aligned 
morphology while proliferation and differentiation were enhanced with the 
stimulation of IGF-1. The released IGF-1 has compensated the inhibitory 
effect of naproxen sodium on tenocytes proliferation, via culturing tenocytes 
on combined scaffolds of NPS fibers and IGF-1 fibers. It is hence concluded 
that the scaffolds that further developed in this chapter could be better 
candidates in promoting tendon healing. 
.
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5.1 Introduction 
 
To tackle on the slow healing issue, growth factors (GFs), a kind of endogenous proteins 
which are capable of stimulating cellular activities involved in the healing of new tissue 
1
, 
have been extensively researched their potential in promoting tendon repair. They are 
commonly prescribed for tissue repair by direct injection into the human body. 
2,3
. 
However, owing to the nature of GFs which degraded easily in vivo (including 
denaturation, oxidation and proteolysis) 
4
, there is insufficient amount of GFs available to 
promote tissue healing by the time they reach the specific target sites of the injury. This 
often results in failure in most phase II clinical trials 
5
. Consequently, large amount of 
GFs are always injected into the body. However, the initial high doses might also lead to 
severe side effect. For instance, vascular endothelial growth factor (VEGF) only 
possesses 30 min half-life while injected intravenously 
6
. Large doses of VEGF were 
hence frequently used; however this supraphysical concentration could result in 
catastrophic pathological vessel formation at non-target sites 
7
. Therefore, enormous 
efforts have been done to incorporate the GFs into the carrier or constructs, such that the 
GFs could be delivered timely, while their bioactivity could be preserved at the same 
time before being released out.  
 
The current approaches for GFs delivery can be categorized into attachment or 
encapsulation techniques 
8
. Despite the relatively easy process to either physically or 
chemically attach the GFs onto the polymers, GFs are commonly entrapped inside 
polymer matrices in order to achieve controllable and slower release as well as preserving 
their biological activities 
9
. Nonetheless, many methods are compromised with burst 
release 
10
, limited duration of release, reduced efficacy 
11
 and formulation complexity 
12
. 
In view of the fluidity of nanoparticles and low mechanical properties of hydrogel 
systems, electrospun fibrous systems are generally deemed as the much more preferable 
GFs delivery vehicles in TE. In fibrous systems, entrapment techniques such as core-shell 
or emulsion electrospinning have been extensively reviewed in loading GFs as well as 
preserving their biological activities in fibers. However, the associated set-up is usually 
very complex and required emulsifying agents in order to stabilize the core or formation 
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of emulsions in solutions 
13
. Besides, several issues such as drug agglomerations on fibers 
surface or inconsistency in forming a continuous core in core-shell fibers, resulting in 
compromise of the mechanical properties of the resultant fibers have been reported 
14,15
.  
 
On the other hand, numerous efforts have been done to load GFs into blend 
electrospinning systems, which require relatively easy set-up and represent higher 
reproducibility. To avoid harsh organic solvents environment, most of these studies are 
focusing on hydrophilic based polymers, such as gelatin or poly(ethylene oxide) 
16-18
. 
However, release of GFs from these matrices could only inevitably last for a few days 
due to faster release. Especially for tendon TE which requires constructs to possess 
longer period of GFs releasing ability 
19
, the aforementioned systems might not be able to 
fit into actual medical practices. Hence, the aim of this chapter is to load GFs into 
hydrophobic polymeric systems via a blend electrospinning system and fabricate an 
aligned electrospun scaffold which is essential for tendon TE, at the same time 
achieving controlled release of GFs.  
 
IGF-1 has been selected because it can promote the synthesis of collagen and 
proteoglycans during the early stage of tendon healing 
20
. In order to ensure that GFs 
loaded into polymers would not lose their native states and ability to function, a suitable 
solvent system is essentially important. Roccatano et al. has reported that HFIP clusters 
which interact with the peptide in HFIP-based solutions could promote the formation of 
ordered secondary structure 
21
. It is then postulated that the bioactivity of the IGF-1 could 
be better preserved after the electrospinning by using HFIP as the solvent and the IGF-1 
release could be controlled by manipulating the polymer compositions. These optimized 
scaffolds were characterized in terms of their morphology, the ability of releasing in vitro 
and potential in inducing tenocytes proliferation and differentiation. The last part of this 
chapter will explore the feasibility of the combined scaffolds (IGF-1 + naproxen sodium 
(NPS, please refer to chapter 4)), in terms of tenocytes proliferation and differentiation in 
promoting tendon regeneration.  
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5.2 Materials and Methods 
 
Relevant information regarding the materials and methodology used in this chapter please 
refer to Chapter 3.  
 
Table 5.1: Methods used in Chapter 5 
Description Section 
Scaffold fabrication Solution preparation 3.2.1.2 
Electrospinning process 3.2.2 
In vitro drug release 3.3.2 
Materials 
characterizations 
Scaffold morphology 3.4.1 
Mechanical properties 3.4.4 
Hydrolytic degradation 3.4.5 
Cell studies Cell seeding 3.5.1.3 / 3.5.1.5 
Cell proliferation 3.6.2.1 / 3.6.2.2 
Immunocytochemistry 3.6.4 
Western Blotting 3.6.5 
Real time quantitative polymerase chain 
reaction (qPCR) 
3.6.6 
 
5.3 Results 
 
5.3.1 HFIP as the solvent for electrospinning 
 
Several solvents have been tested for their capability to preserve IGF-1 stability. Figure 
5-1 shows the relative protein stability in different solvents (determined by ELISA) after 
freeze-drying process. The stability of these samples was compared to the freshly 
prepared IGF-1 protein solution as the standard set at 100% stability. IGF-1 showed the 
least stability after loading into dichloromethane (DCM), inside which around 44% of 
protein was detected. In contrast, IGF-1 which was loaded into the water could maintain 
its stability up to around 90%. IGF-1 which was diluted in HFIP showed a stability of 
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about 80%, which could be further enhanced with the inclusion of PEO into the HFIP 
solution, yielding a stability of about 96%. 
 
 
Figure 5.1: Graph showing the relative IGF-1 stability in different solvents. HFIP showed relatively better 
ability in preserving IGF-1 stability as compared to DCM. (* indicates p < 0.05, ** indicates p < 0.001) 
 
By using HFIP as the solvent, electrospinning of IGF-1-loaded scaffolds were conducted 
by using mandrel set up, with different formulations as stated in Table 5.2. Scaffolds were 
named according to their concentration, followed by PLGA-PCL ratio and whether with 
or without PEO in the formulations. For example, 8-70/30-0 indicates 8 w/v% of polymer 
with the composition of 70wt% PLGA blended with 30wt % PCL, and 0 wt% of PEO in 
the formulation. 
 
Table 5.2: Description of different formulations of electrospinning solutions. 
Samples  
Total 
Concentration 
(w/v%)  
PLGA 
(wt %)  
PCL 
(wt %)  
PEO 
(wt %)  
A  8-80/20-0  8  80  20  0  
B  8-70/30-0  8  70  30  0  
C  8-70/30-5  8  66.5  28.5   5  
D 5-70/30-5  5 66.5   28.5 5  
E 3-70/30-5  3  66.5   28.5  5  
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Figure 5.2 shows the FESEM images of scaffolds prepared by using different 
formulations. All the scaffolds possessed aligned morphology to mimic the tendon cells 
micro-environment, while the fiber diameters were all in the submicron range. 
 
  
  
  
Figure 5.2: FESEM images of IGF-1 loaded scaffolds: A) 8-80/20-0; B) 8-70/30-0; C) 8-70/30-5; D) 5-
70/30-5; E) 3-70/30-5. (F) The fiber diameter analysis showed that lowering the concentration decreased 
the fiber diameter. (* indicates p < 0.05) 
 
 
 
A B 
C D 
E F * p < 0.05  
Scaffold Types 
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5.3.2 Controlled IGF-1 release from the electrospun scaffolds 
 
Figure 3 shows that the in vitro released amount of bioactive IGF-1 (determined by using 
ELISA kit) from the scaffolds fabricated from the different formulations. Figure 5.3A 
shows the amount of IGF-1 being released when the scaffolds were fabricated by using 
different PLGA:PCL ratios. It was observed that IGF-1 was released faster with higher 
percentage of PCL content. With the presence of PEO in the fibers, the release of IGF-1 
was faster as shown in Figure 5.3B. As depicted in Figure 5.3C, the release of IGF-1 
could be further enhanced: from 600pg/week to 1000pg/week to 1700pg/week, while the 
total polymer concentration of the formulations was decreased from 8w/v% to 5w/v% to 
3w/v. By using the scaffold which was fabricated from the formulation E as described in 
Table 5.2 (i.e. 3w/v% of total polymer concentration, with 66.5wt% of PLGA and 28.5wt% 
of PCL and 5wt% of PEO as additives), long term release study was conducted and 
release of IGF-1 was observed to have continued for about 10 weeks (Figure 5.3d). The 
total IGF-1 loaded inside the polymers was determined by using microBCA assay. After 
extraction, there was about 76% of IGF-1 encapsulated inside the polymers. 
 
 
A) 
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Figure 5.3: Release prolife of IGF-1 under different formulations: A) different polymer ratios; B) with or 
without PEO; C) different polymer concentration. D) Release of IGF-1 from the optimized scaffold (i.e. 3-
70/30-5) lasted for 10 weeks. 
 
B)  
C) 
D) 
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5.3.3 Mass loss and change in molecular weight from 3
rd
 week 
 
Mass loss measurement and size exclusion chromatography were conducted in PBS 
solution to understand the degradation of the IGF-1 scaffolds and the empty scaffolds. As 
shown in Figure 5.4, the inclusion of IGF-1 did not alter the degradation. Both scaffolds 
started to have significant mass loss (Figure 5.4a) and molecular weight change (Figure 
5.4b) from 3
rd
 week of the study onwards. It should be noted that the scaffolds have 
insignificant morphological change throughout the study. 
 
 
 
 
Figure 5.4: Plots showing IGF-1 and empty scaffolds degraded from 3
rd
 week onwards, from the evidence 
of A) mass loss and B) molecular weight change. 
 
A) 
B)  
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5.3.4 Released IGF-1 maintained bioactivity 
 
Western Blotting technique was used to visualize the phosphorylation level of protein 
kinase B, also known as Akt to determine the bioactivity of the release IGF-1. Briefly, 
IGF-1 scaffolds were immersed into culture medium for 1 day and 7 days respectively. 
These preconditioned mediums were then exposed to confluent C2C12 cells for 30 min 
before the cells were lysed and checked for the phosphorylated Akt level by using 
Western Blot technique. Figure 5.5a, Figure 5.5b and Figure 5.5c show that the 
immunoblots for phosphorylated AKT (Ser473), total AKT and β-Actin antibodies 
respectively. The graph of Figure 5.5d shows the densitometry analysis, obtained by 
normalizing bands intensity of the immunoblots. The densitometry analysis showed that a 
7-fold and 17-fold up-regulation of the phosphorylated Akt level in the cells which were 
treated under 1-day and 7-day IGF-1 scaffold preconditioned mediums, respectively. The 
expression of 1-day empty scaffold preconditioned medium was set as the standard at 1. 
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 Immunoblots 
A)  
pAkt 
Ser473     
B)  
Total Akt 
    
C)  
β-Actin 
     
 Empty IGF-1 Empty IGF-1 
1-day preconditioned medium 7-day preconditioned medium 
   
D  
 
Figure 5.5: Immunoblots showing the expression of A) pAkt Ser473, B) total Akt and C) β-Actin while the 
cells cultured on IGF-1 scaffolds and empty scaffolds were exposed to 1-day and 7-day preconditioned 
mediums. D) Densitometry analysis of the blots showed that the up-regulated of Akt phosphorylation 
indicated that IGF-1 is bioactive after the encapsulation. 
 
5.3.5 Released IGF-1 retained functionality by enhancing C2C12 cells proliferation 
and differentiation 
 
C2C12 cells were cultured on scaffolds and the proliferation was determined by using 
AlamarBlue assay and PicoGreen Assay. Figure 5.6a shows that the cells, which were 
seeded on IGF-1 scaffolds, proliferated faster from day 1 to day 3 as determined by using 
AlamarBlue assay. Similarly, PicoGreen analysis showed that the cells proliferated faster 
* p < 0.05 
Preconditioned medium types 
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on IGF-1 scaffolds compared to empty scaffolds, as shown on Figure 5.6b. Notably, both 
assays suggested that there were higher number of cells on IGF-1 scaffolds compared to 
empty scaffolds for every predetermined time points. 
 
 
Figure 5.6: Graphs showing the C2C12 cells proliferated throughout the study as determined by A) 
AlamarBlue assay and B) PicoGreen assay. Cells on IGF-1 scaffolds proliferated faster compared to empty 
scaffolds. (* indicates p < 0.05) 
 
Figure 5.7 shows the nucleus staining images of C2C12-seeded scaffolds. From Figure 
5.7A, the cells became confluent on IGF-1 scaffolds after culturing for 3 days whereas 
cells only became confluent after culturing on empty scaffolds for 7 days (Figure 5.7C). 
 
A 
B 
* p < 0.05 
* p < 0.05 
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Figure 5.7: Immunostaining images showing A) C2C12 (nuclei was stained blue) reached almost 100% of 
confluency after culturing for 3 days on IGF-1 scaffolds; however, B) fewer cells were observed on empty 
scaffolds on day 3, and C) cells only become confluent after 7 days of culture on empty scaffolds. (scale bar 
= 50µm) 
 
Real time polymerase chain reaction (qPCR) was utilized to evaluate the differentiation 
tendency of the C2C12 cells on the scaffolds. C2C12 cells were cultured on IGF-1 and 
empty scaffolds until confluent (i.e. 3 days and 7 days respectively) prior to changing the 
culture medium to differentiation medium. As shown in Figure 5.8, significant up-
regulation of myogenin gene (2-fold change) was observed after 1 day as differentiation 
of the cells was being induced. The myogenin gene expression was leveled off 3 days 
after changing the medium into differentiation medium. The differentiation was further 
ascertained at translational level through the immunostaining of desmin protein which 
was shown in Figure 5.9. From the images, more and larger multinucleated fibers or 
―myotubes‖ which formed through the fusion of cells were observed on IGF-1 scaffold 
(Figure 5.9A) compared to empty scaffold (Figure 5.9B).  
 
 
 
 
A B C 
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Figure 5.8: Graphs showing myogenin expression of C2C12 on A) day 0, B) day 1 and C) day 3 of 
differentiation. The myogenin expression on IGF-1 scaffolds was up-regulated compared to empty 
scaffolds after 1 day of differentiation but it was leveled off on day 3. (* indicates p < 0.05) 
 
B) 
A) 
C) 
* p < 0.05 
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Figure 5.9: Immunostaining images showing myotubes formation on A) IGF-1 scaffolds and B) empty 
scaffolds, where more and larger myotubes were observed on IGF-1 scaffolds. (scale bar = 50µm) 
 
5.3.6 Tenocytes proliferated and differentiated on IGF-1 loaded scaffolds 
 
Figure 5.10 shows that the tenocytes proliferated relatively faster on IGF-1 scaffolds 
compared to empty scaffolds, as determined by using PicoGreen assay (p < 0.05). 
Besides, immunostaining images from Figure 5.11 shows that more cells could be 
observed on IGF-1 scaffolds (Figure 5.11A) as compared to empty scaffolds (Figure 
5.11B). 
 
Figure 5.10: Graph showing tenocytes proliferated on IGF-1 and empty scaffolds, as determined by 
PicoGreen Assay. Tenocytes proliferated faster on IGF-1 scaffolds compared to empty scaffolds. (* 
indicates p < 0.05) 
 
A) B) 
* p < 0.05 
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Figure 5.11: Immunostaining images showing more tenocytes were on a) IGF-1 scaffolds than on b) empty 
scaffolds, where tenocytes were immunolabeled with phalloidin (red) to show cytoskeleton of the cells and 
counterstained with DAPI (blue) to indicate nucleus. (scale bar = 50µm) 
 
The differentiation tendency of the tenocytes was determined by qPCR technique. As 
shown in Figure 5.12, gene expression of scleraxis (Figure 5.12A) showed 3-fold 
increment on IGF-1 scaffold after culturing for 3 days while the tenomodulin (TNMD, 
Figure 5.12b) gene expression was up-regulated on IGF-1 scaffolds compared to empty 
scaffolds on day 3 and day 7. Although the tendon specific gene markers (i.e. Scleraxis 
and TNMD) were up-regulated, no significant difference was observed in terms of 
collagen I gene expression (Figure 5.12c) for both IGF-1 scaffolds and empty scaffolds. 
 
 
 
 
 
 
 
A) B) 
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Figure 5.12: Graphs showing tendon specific genes: A) scleraxis and B) tenomodulin were up-regulated in 
tenocytes cultured on IGF-1 scaffolds compared to empty scaffolds; however no much difference was 
observed in C) collagen I gene expression on both types of scaffolds. (* indicates p < 0.05) 
 
5.3.7 Released IGf-1 rescued tenocytes proliferation and differentiation on 
combined scaffolds 
 
Tenocytes were then seeded onto combined scaffolds (either with or without IGF-1 
integrated with NPS scaffolds) and the cell proliferation was determined by using 
A) 
C) 
B) 
* p < 0.05 
* p < 0.05 
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PicoGreen assay, as shown in Figure 5.13. Proliferation of tenocytes were affected with 
the presence of NPS, in which less proliferation was observed on empty scaffolds + NPS 
scaffolds; however, the released IGF-1 has compensated this influence and significant 
proliferation was observed on IGF-1 scaffold + NPS scaffold from day 1 to day 7. On day 
7, there were also more cells on IGF-1 scaffolds + NPS scaffolds compared to empty 
scaffold + NPS scaffold (p <0.05). 
 
 
Figure 5.13: Graph showing tenocytes proliferated faster on IGF-1 Scaffold + NPS scaffold than Empty 
Scaffold + NPS scaffold, as determined by PicoGreen Assay. (*indicates p < 0.05) 
 
The differentiation tendency for tenocytes on the combined scaffolds was again 
determined by checking the scleraxis, tenomodulin and collagen I gene expression by 
using qPCR (Figure 5.14). There was significant up-regulation of scleraxis and 
tenomodulin gene expressions when tenocytes were cultured on IGF-1 scaffold + NPS 
scaffold, compared to that of when cultured on empty scaffold + NPS scaffold. 
 
* p < 0.05 
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Figure 5.14: Graphs showing tendon specific genes: A) scleraxis; B) tenomodulin were up-regulated when 
tenocytes were cultured on IGF-1 scaffold + NPS scaffold; however, there was slightly higher expression of 
C) collagen I expressed on IGF-1 scaffold + NPS scaffold. (* indicates p < 0.05) 
 
 
 
A 
B 
C 
* p < 0.05 
* p < 0.05 
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5.3.8 Combined scaffolds possess optimal mechanical properties 
 
Table 5.3 summarizes the apparent Young‘s modulus (Eapp) of IGF-1 scaffolds, NPS 
scaffolds and combined scaffolds. Combined scaffolds, which was fabricated through 
electrospinning of NPS scaffolds followed by IGF-1 scaffolds sequentially, possess a 
Young‘s modulus of about 148.75 ±16.76 MPa, which lies between the Young‘s modulus 
of pure NPS scaffolds (i.e. Eapp = 272.15 ±8.38 MPa) and pure IGF-1 scaffolds (i.e. Eapp = 
105.65 ± 8.37 MPa). 
 
Table 5.3: Apparent Young‘s modulus of NPS scaffolds, IGF-1 scaffolds and combined scaffolds 
Scaffolds Apparent Young’s Modulus (MPa) 
NPS scaffolds 272.15 ±8.38 
IGF-1 scaffolds 105.65 ± 8.37 
Combined scaffolds 148.75 ±16.76 
 
5.4 Discussion 
 
It has been demonstrated that scaffolds which are able to release biomolecules, have 
therapeutic benefits in encouraging tissue formation either in in vitro culture or in vivo 
environment 
22-25
. However, preserving GFs conformation is critical as the loss of 
conformation of GFs could reduce their intended therapeutic potential and cause 
unwanted immunogenic effects due to exposure of nonnative peptide epitope 
26,27
. 
Generally, GFs delivery in fibrous systems could be achieved through chemical 
immobilization or physical entrapment into the polymer matrices 
28-32
. For the latter, it 
allows better GFs bioactivity stability and protection against the outer environment. Even 
so, GFs are inevitably susceptible to various risks of degradation, either during 
fabrication and release 
33,34
. In the present study, electrospinning from blended solution 
was employed and HFIP was selected to be the solvent for electrospinning. This is 
because IGF-1 stability in HFIP was higher at 76% compared to IGF-1 stability in DCM 
at 44%. Unlike DCM, HFIP does not create organic-inorganic interface where proteins 
tend to aggregate, unfold and lose its nature states 
10,35
. Hence, with the use of HFIP as 
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the electrospinning solvent, IGF-1 bioactivity could thus be better preserved.  
 
Protein release from nanofibers occurs through a combination of material degradation or 
passive diffusion across nanopores on the fiber surface 
36,37
. In the attempt of releasing 
IGF-1 from the scaffolds presented in this chapter, a relatively low amount of IGF-1 was 
being released when PLGA alone was used as the polymeric vehicle. PCL was thus added 
into the electrospinning formulation to fasten the IGF-1 release as PCL chains could 
allow higher water penetration into the fibers to facilitate the IGF-1 release 
38
. The 
addition of PCL also aided in preventing the possible shrinkage of the scaffolds though 
obstructing the PLGA chains movement 
39
. PEO was further added into the formulation 
to accelerate the release of IGF-1. The addition of PEO was believed to have facilitated 
the release of IGF-1 through enhancing the hydrophilicity of the scaffolds and at the same 
time, introduced tiny pores to the matrices to facilitate the IGF-1 release 
40,41
. 
Interestingly, with the inclusion of PEO, IGF-1 stability could also be improved to about 
96%. This might be due to the use of hydrophilic additives such as PEO which can 
minimize the hydrophobic interaction of IGF-1 and the solvent environment and thus 
further preserve the stability of IGF-1 
42
. The total polymer concentration was then 
further reduced to adjust the daily released of IGF-1 amount and the optimized 
formulation was set at 3w/v% polymer concentration, with the PLGA:PCL fixed at ratio 
of 70:30 and 5wt% PEO as additives. This is because lower polymer concentration could 
yield fibers with smaller diameter hence resulting in higher specific surface area to 
facilitate the IGF-1 release 
43,44
. However, it should be noted that electrospinning 
solutions with too low in polymer concentration (i.e. < 3w/v%) would compromise on the 
electrospinability due to insufficient polymer entanglements 
45
. With this optimized 
formulation, long term drug release study was conducted and lasted for about 10 weeks. 
The release profile could be divided into three phases. In phase 1, IGF-1 was released 
sustainably with daily release of 300pg/mL up to 1 week. It was followed by a relatively 
slow release (phase 2) and the scaffolds started releasing faster from third week onwards 
(phase 3) and came to a stop around 10
th
 week of the study. The first phase of the release 
was believed to be related to the dissolution of PEO and it has contributed to the release 
of IGF-1 which was resided near to the fiber surface. In phase 2, relatively smaller 
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amount of IGF-1 was released before the polymer blends started to degrade. After 3 
weeks, the scaffolds started to degrade as supported by the evidence of mass loss and 
slight molecular weight change of the scaffolds (Figure 5.4A and Figure 5.4B). In this 
third phase, IGF-1 was further released until 10 weeks. It is noted that less amount of 
bioactive IGF-1 was detected by using ELISA throughout the study, compared to the total 
loaded amount of IGF-1 (encapsulation efficiency of 76%). This could be due to the 
possible denaturation either during the electrospinning process or throughout the study 
46,47
. Besides, other possible reasons could be the incomplete detection of released IGF-1, 
which has been absorbed back to the polymeric surface after releasing out from the 
matrices 
27,48
. 
 
With controlled release being achieved, the next important factor to consider is that the 
released IGF-1 should be able to trigger the relevant cellular response to prove their 
efficacy. Scheme 5-1 depicts the simplified IGF-1/Akt pathway. Generally, binding of 
IGF-1 to its receptor results in activation of tyrosine kinase and phosphorylation of 
insulin receptor substrate (IRS), which further activates cascades of phosphorylation and 
hence leading to Akt activation. Immunoblotting of Akt protein in C2C12 cells has 
demonstrated that the bioactivity of IGF-1 was maintained after the encapsulation process 
(Figure 5-4). Akt stimulates protein production via the mammalian target of rapamycin 
(mTOR), and subsequently contributes to hypertrophy in skeletal muscles 
49
. 
 
 
Figure 5.15: Schematic diagram showing simplified IGF-1/Akt pathway. 
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It is worth to note that the released IGF-1 was also able to further trigger the downstream 
cellular response. Figure 5.6 has shown the enhancement of cell proliferation with the 
culture of C2C12 cells on IGF-1 scaffolds. The differentiation of C2C12 cells was also 
promoted, as demonstrated by the up-regulation of myogenin gene expression at 
transcriptional level (Figure 5.8) and immunostained multinucleated cells or ―myotubes‖ 
formation at translational level (Figure 5.9). Myogenin is a muscle-specific basic-helix-
loop-helix transcription factor, which is essential for the development of functional 
skeletal muscle while the myotube formation indicates myogenesis 
50-53
. Engert et al. 
reported similar observation in their IGF-1-stimulated myogenesis study, in which IGF-1 
was found to enhance cell proliferation and promoted larger myotubes formation at the 
later stage of the study 
54
. These results have demonstrated that the released IGF-1 was 
bioactive and able to induce relevant cellular response. 
 
Several in vitro studies have reported the successful tendon tissue engineering either by 
mechanical stimulation 
55,56
, knitted scaffolds 
57
, using different cell sources 
58,59
 or 
introducing growth factors 
60,61
. IGF-1 is well known for their ability in stimulating the 
proliferation and migration of cells. It is also known to subsequently increase the 
collagens synthesis during the remodeling stages 
62
. In the present study, tenocytes were 
able to proliferate faster under the influence of IGF-1 and adopt their typical elongated 
aligned morphology by going along with the topographical cues from the scaffolds. 
Besides, the expression of tendon specific genes such as scleraxis and tenomodulin were 
also up-regulated with the stimulation of IGF-1released from the scaffolds. Scleraxis and 
tenomodulin have been demonstrated their important role in regulating tendon 
proliferation and maturation 
63-65
. The IGF-1 scaffolds were then sequentially electrospun 
with the previously optimized NPS scaffolds. As mentioned in Chapter 4, the purpose of 
having NPS is to prevent adhesion formation during the healing process, as it might lead 
to recurrent injury due to improper healing 
66
. In spite of its beneficial role in preventing 
inflammation and providing analgesic effect, it has been shown that NPS could interfere 
with tendon healing through inhibiting the tenocytes proliferation and associated collagen 
synthesis 
67,68
. Indeed, the proliferation of the tenocytes in this work was reduced by the 
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release of NPS as demonstrated in Chapter 4. However, the released IGF-1 recovered the 
loss in proliferation as shown in Figure 5.13. It should also be noted that the tendon-
related genes such as scleraxis and tenomodulin have also been up-regulated to show the 
tendency of differentiation. In addition, this combined scaffold (IGF-1 scaffold + NPS 
scaffold) presented optimal mechanical properties with apparent Young‘s modulus of 
148.75 ± 16.76 MPa (Table 5.2), which is sufficient to withstand the cyclic loading 
normally applied for improving the tendon regeneration 
69,70
. It is therefore believed that 
the scaffolds, which possess morphological cues to guide cellular growth and the NPS 
and IGF-1 releasing ability, presented in this study will be a beneficial add-on for the 
current research to achieve better tendon regeneration.  
 
5.5 Summary 
 
In this chapter, IGF-1 was successfully incorporated into PLGA/PCL aligned electrospun 
scaffold. Release of IGF-1 lasted for about 10 weeks, and results showed that released 
IGF-1 preserved their bioactivity and was able to trigger C2C12 downstream cellular 
response. Tenocytes cultured on the scaffolds adopted their typical elongated aligned 
morphology while proliferation and differentiation were enhanced with the stimulation of 
IGF-1. Although NPS has slightly inhibited tenocytes proliferation and differentiation, 
the released IGF-1 has compensated the loss via culturing on combined scaffolds of NPS 
fibers and IGF-1 fibers. It is hence concluded that the scaffolds that further developed in 
this chapter could be better candidates in promoting tendon healing. 
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Chapter 6  
 
Medium compatibility study for tri-culture of C2C12, 
tenocytes and TE85 
 
The musculoskeletal interfaces are susceptible to injuries. However, the 
regeneration at this translational region is always suboptimal and thus lead 
to recurrent injury. In view of the necessity of having an in vitro 
musculoskeletal model which will allow different tissues interaction, three 
types of cells, namely C2C12, tenocytes and TE85 were cultured on an 
insulin-like growth factor containing scaffold under the same medium 
environment. PicoGreen analysis, PCR results and immunolabeling of 
differentiation markers have shown that these cells survived, proliferated 
and differentiated under the optimized medium conditions. The co-existence 
of these three types of cell in a general in vitro environment implies the 
possibility of re-creating the muscle-tendon-bone configuration. With the 
knowledge obtained from this in vitro musculoskeletal model, the quality of 
the biological tools and the approaches for therapeutic agents’ discovery 
could be significantly improved. 
 
.
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6.1 Introduction 
 
The musculoskeletal interfaces where tendon connects to bone and muscle (i.e. 
osteotendinous junction and myotendinous junction respectively) are always subjected to 
frequent large mechanical stress and hence making these junctions vulnerable to acute or 
overuse injuries 
1
. To repair these regions, the gold standard is to suture grafts at these 
anchorage sites 
2
. However, due to the lack of graft integration with their attachment sites, 
these grafts fail easily 
3-5
. In view of the fact that these regions are generally not 
homogeneous and have natural functional gradients in their structure 
6
, interface tissue 
engineering thus stands out and emphasizes the necessity of having graded materials to 
meet the structural and mechanical demand of these translational tissues 
7-10
. Although 
several reports indicated the possibility of improving tissue regeneration at this 
translational region, most studies in interface tissue engineering focused on the scaffold 
design 
11-17
; whereas the culture conditions to cultivate the cells in vitro so as to 
regenerate a partially formed constructs have been inadequately addressed. Especially in 
tendon TE, instead of just having a graded scaffold for implantation, a partially formed 
tissue constructs is much more preferred for their ability to yield optimal mechanical 
strength at the time of implantation. This will allow the onset of physical therapy soon 
after surgery, and thus for functional recovery 
18,19
. Hence, in this chapter, an in vitro 
musculoskeletal model was proposed. Three types of cells, namely C2C12 murine 
myoblast, tenocytes and TE85 human osteosarcoma (to represent muscle-like, tendon and 
bone-like cells respectively) were seeded onto previously optimized IGF-1 loaded 
scaffolds, and the in vitro culture condition (i.e. culture medium) was optimized in 
order to provide the optimal environment for the proliferation and differentiation of 
these three cells. This chapter emphasizes on sourcing for the general medium for 
culturing these three types of cell simultaneously, with the postulation that a graded tissue 
similar to that at the native structure could be formed via promoting heterotypic 
interactions between different cells in close proximity. 
In vitro tri-culture muscle/tendon/bone model Chapter 6 
97 
 
6.2 Materials and Methods 
 
For the information regarding the materials and methodology used in this chapter, please 
refer to Chapter 3. 
 
Table 6.1: Methods used in Chapter 6 
Description Section 
Scaffold fabrication Solution preparation 3.2.1.2 
Electrospinning process 3.2.2 
Cell studies Cell seeding 3.5.1 
Cell proliferation 3.6.2.1 
Real time quantitative polymerase chain 
reaction 
3.6.6 
Immunocytochemistry 3.6.4 
Alizarin red S staining 3.6.7 
 
 
6.3 Results 
 
For the medium compatibility study, different types of growth medium and differentiation 
medium were used as illustrated in Table 6.2.  
 
Table 6.2: Mediums and their compositions used for tri-culture systems 
Medium Medium Composition 
GM1 High Glucose DMEM + 20% FBS + 1% P/S 
GM2 Low Glucose EMEM + 10% FBS + 1% L-Glut+ 1% NEAA 
+ 1% P/S 
DM1 High Glucose DMEM + 2% HS  + 1% P/S 
DM2 Mixture of 1:1 of DM1 and DM3 
DM3 Low Glucose DMEM + 10% FBS + 1% P/S + 0.05mM 
ASB + 10 mM β-Gly + 0.1µM DEX 
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DM4 High Glucose DMEM  + 2% HS + 1% P/S + 0.05mM ASB 
+ 10 mM β-Gly 
DM5 High Glucose DMEM + 2% HS + 1% P/S + 0.05mM ASB 
+ 10 mM β-Gly + 0.1µM DEX 
 
6.3.1 C2C12 proliferated on IGF-1 scaffold, regardless of the glucose level of the 
medium used 
 
Figure 6.1: Optical microscopic images showing C2C12 cultured on well plates in different growth 
mediums proliferated and adopted typical spindle shaped morphology after 1 day (1D), 2 days (2D) and 4 
days (4D) of culture. (scale bar = 100µm) 
 
Figure 6.1 shows the optical microscopic images of the C2C12 cells cultured on well 
plates in GM1 and GM2. In both mediums, the cells adopted their typical spindle shaped 
morphology and proliferated throughout the study. C2C12 cells were then seeded onto 
IGF-1 scaffolds and cultivated in both types of medium. As shown in Figure 6.2, 
PicoGreen assay demonstrated that C2C12 cells proliferated from day 1 to day 3 on IGF-
1 scaffolds in both mediums (p < 0.05), though proliferation was slightly faster in GM1 
than in GM2. 
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Figure 6.2: Graph showing the C2C12 proliferated on IGF-1 scaffolds in both GM1 and GM2, as 
determined by PicoGreen Assay. (* indicates p < 0.05) 
  
6.3.2 Glucose level of the medium does not interfere TE85 proliferation on IGF-1 
scaffold 
 
Similarly, TE85 were cultured in the same conditions as C2C12 cells. Figure 6.3 shows 
the TE85 cells exhibited their typical cell shapes and more cells were observed after 
culturing for 4 days on well plates. The cells numbers cultured on IGF-1 scaffolds were 
further quantified by using PicoGreen assay as depicted in Figure 6.4. In both medium, 
TE85 proliferated throughout the study, while they grew slightly better when cultured in 
GM2. 
 
* p < 0.05 
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Figure 6.3: Optical microscopic images showing TE85 proliferated and adopted their typical morphology 
on well plates (scale bar = 100µm) 
 
 
Figure 6.4: Graph showing the TE85 proliferated on IGF-1 scaffolds in both GM1 and GM2, as determined 
by PicoGreen Assay. (* indicates p < 0.05) 
 
6.3.3 Tenocytes able to proliferate on IGF-1 scaffolds, regardless of the medium 
types. 
 
GM1 and GM2 were used to investigate for their compatibility in terms of tenocytes 
proliferation. As shown in Figure 6.5, tenocytes proliferated throughout the study, 
although slightly lower proliferation was observed while cultured in GM2.  
 
* p < 0.05 
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Figure 6.5: Graph showing the tenocytes proliferated on IGF-1 scaffolds in GM1 and GM2, as determined 
by PicoGreen Assay. (* indicates p < 0.05) 
 
6.3.4 C2C12 formed myotubes in high glucose conditions 
 
C2C12 cells were cultured on IGF1 scaffolds in GM1 until confluent (3 days in growth 
medium) before changing the culture condition to different types of differentiation 
mediums. The cells were allowed to differentiate for another 4 days before they were 
fixed and stained for desmin protein to visualize myotube formation. As illustrated in 
Figure 6.6, myotubes were only formed and observed when DM1, DM4 and DM5 were 
used as shown in Figure 6.6A, Figure 6.6D and Figure 6.6E respectively. Whereas, few 
cells were observed when osteogenic differentiation medium (DM3) or 1:1 mixture of 
myogenic and osteogenic differentiation medium (DM2) were used, as shown in Figure 
6.6C and Figure 6.6B respectively. 
 
For studies using DMs which induced myotubes formation, C2C12 cells were analyzed 
for their myogenic differentiation tendency. Figure 6.7 shows that myogenin gene was 
indeed up-regulated even though myogenin gene expression was peaked on day 1 and 
then leveled off for cells differentiated in DM5 . 
 
* p < 0.05 
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Figure 6.6: Immunostaining images showing ―myotubes‖ formation on IGF-1 scaffolds which were 
immunolabeled by desmin (red) and nucleus (blue) while C2C12 were induced differentiation in A) DM1; 
D) DM4 and E) DM5; lesser cells were observed while C2C12 were subjected to B) DM2 and C) DM3. 
(scale bar = 50µm). 
A B 
C D 
E 
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Figure 6.7: Graph showing myogenin expressions were up-regulated when C2C12 were cultured on IGF-1 
scaffolds in DM1, DM4 and DM5. 
 
6.3.5 Osteogenic supplements are essential for TE85 calcium deposition 
 
Alizarin red s staining has been employed to determine the calcium deposition of TE85 
cells, which indicates the mid to late stage of the osteogenic differentiation. TE85 were 
firstly cultured in GM1 for 3 days until confluent in the well plates, and subsequently 
changing to different types of differentiation medium to check their capability to induce 
TE85 osteogenic differentiation. TE85 was also cultured in their typical growth medium 
(GM2) and changed to osteogenic differentiation medium (DM3) as the control. TE85 
were cultured for another 28 days before they were fixed and stained for calcium 
deposition. Figure 6.8 shows the amount of calcium deposited by TE85 cells cultured in 
different mediums; with DM3 (Figure 6.8D) resulting the most calcium deposition, 
followed by DM5 (Figure 6.8C), DM4 (Figure 6.8B) and DM1 (Figure 6.8A) in 
descending order. The Runx2 markers (early osteogenic differentiation markers) were 
also checked on the cells cultured on IGF-1 scaffolds and the gene expression was 
observed to be up-regulated (Figure 6.9). Calcium deposition was visualized by using 
alizarin red s staining to further confirm their osteogenic lineage commitment (Figure 
6.10). 
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Figure 6.8: Alizarin red s staining showing the amount of calcium deposition, when TE85 cultured in well 
plates, was in the order of D) DM3 > C) DM5 > B) DM4 > A) DM1. (scale bar = 50mm for upper deck 
images, 10µm for lower deck images) 
 
 
 
 
Figure 6.9: Graph showing Runx2 expression was up-regulated while TE85 were cultured on IGF-1 
scaffolds in DM3, DM4 and DM5. 
 
 
 
 
A B C D 
__ __ __ __ 
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Figure 6.10: Macroscopic images showing calcium deposition which was visualized through alizarin red s 
staining while TE85 were cultured on IGF-1 scaffolds in (A) DM4, (B) DM5 and (C) DM3 as compared to 
(D) control which is acellular sample. (scale bar = 50 mm) 
 
6.3.6 Tendon specific genes were slightly down-regulated in optimized medium 
 
Tenocytes were cultured in GM1 for 3 days and changed to differentiation medium, DM5. 
After culturing for 4 days, as shown in Figure 6.11, tendon specific genes such as 
scleraxis and tenomodulin were slightly down-regulated (though not significantly) as 
compared to culturing tenocytes in the control medium (i.e. tenocytes original growth 
medium (GM3)). 
  
B A C D 
__ __ __ __ 
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Figure 6.11: Graphs showing tendon specific genes: A) scleraxis, B) tenomodulin and c) collagen I were 
slightly down-regulated while tenocytes were cultured on IGF-1 scaffolds in DM5 as compared to in GM3. 
 
6.3.7 Tri-culture of C2C12/Tenocytes/TE85 on IGF-1 scaffolds 
 
In the last part of the study, C2C12, tenocytes and TE85 were seeded onto the IGF-1 
scaffolds. After culturing in GM1 for 3 days, constructs were changed into DM5 and 
cultured for another 4 days. As shown in Figure 6.12, Runx2-immunolabeled TE85 cells 
B 
A 
C 
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were grown at one end of the scaffolds, while C2C12 cells were immunolabeled by using 
anti-myogenin antibody resided at the other end of the scaffolds. Tenocytes, which were 
counterstained with DAPI to visualize the nucleus, grew at the centre of the scaffolds. 
Three types of cells could survive, proliferate and differentiate in the optimized medium, 
as shown in Figure 6.12. 
 
Figure 6.12: Immunostaining images showing the co-existence of TE85 (immunolabeled with RUNX 
marker, green), tenocytes and C2C12 (immunolabeled with myosin heavy chain, red) and their nucleuses 
were counterstained by using DAPI. (scale bar = 50 µm)  
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6.4 Discussion 
 
Tissue regeneration at the interface, especially regions with mechanical mismatch such as 
osteotendinous junction, is often unsuccessful and hence requires re-surgery. This could 
be due to the fact that the native feature at this region, which possesses gradients in 
mineral content and collagen organization, often fails to be re-created during the natural 
healing process 
20,21
. Thus, TE approach which includes multi-lineage cell culture 
methods and the fabrication of biomimetic scaffold has been explored to regenerate this 
specialized transitional region. For example, graded bone-like minerals were deposited on 
the surface of electrospun scaffold to imitate the composition and mechanical function of 
the osteotendinous junction 
12,22-25. Additionally, ―aligned-to-random‖ fibers transition 
was also created to mimic the collagen fibers organization at the tendon-to-bone insertion 
site 
26-28
. Apart from this, regeneration at the muscle-tendon interface or myotendinous 
junction (MTJ), which is critical for integrative tendon repair, has been explored to 
improve the tendon repair. Larkin et al. co-cultured skeletal constructs with engineered 
tendon constructs and showed that the MTJ formed could sustain tensile loading and 
paxilin was up-regulated at the neo-interface 
29
. However, studies on tri-culture systems 
relating to bone-tendon-muscle are still under-explored. Considering that the supplements 
required to tissue engineer these tissues could be very different and might cause 
detrimental effects towards other cell types in the in vitro system 
30-33
, we have tissue-
engineered C2C12 murine myoblast (muscle-like cells), tenocytes (tendon cells) and 
TE85 human osteosarcoma (bone-like cells) in an in vitro tri-culture platform using IGF-
1 scaffolds. This study seeks to understand and provide optimal condition for tri-culture 
of these cells. 
 
Firstly, C2C12 which has been commonly used to study the myoblast differentiation 
34-37
, 
were subjected to high glucose (GM1) and low glucose DMEM (GM2) to check their 
proliferation in these conditions. As shown in Figure 6.2, the proliferations in both 
conditions were not affected by the glucose difference and the cells maintained their 
morphology. However, while C2C12 were subjected to differentiation, the low level of 
glucose was unable to promote the cell fusion and most of the cells detached in DM2 and 
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DM3. Similar phenomenon was also observed in Fulco et al.‗s work where glucose 
restriction has inhibited the myogenesis through activation of AMP-activated protein 
kinase 
38
. For those cells differentiated in high glucose level of medium, myogenin gene 
expression was up-regulated and myotubes were successfully formed. Notably, myotubes 
were also successfully formed in DM 5 which consisted of dexamethasone. Generally, 
dexamethasone is the compound which is known to favor the expression of the 
osteogenesis 
39-41
. However, the presence of dexamethasone could cause atrophy in 
skeletal muscle which was correlated with the up-regulation of myostatin promoter 
activity 
42,43
. The myotube formation in DM5 in the study could be due to the synergistic 
differentiation which produced hypertrophic myotubes after the treatment of C2C12 cells 
with the released IGF-1 in combination with dexamethasone 
44-47
. As a summary, the 
medium type has less effect towards the proliferation of C2C12 cells; however, glucose 
restriction (i.e. low glucose environment) could inhibit the myogenesis in differentiation 
phase. With these results, only DM1, DM4 and DM5 would be further evaluated for their 
capability in inducing mineralization for the TE85 osteogenesis determination. 
 
TE85 human osteosarcoma, which is commonly used for osteoblast differentiation study 
48,49
, has been used to represent the bone-like cells in the proposed musculoskeletal model. 
In the present study, the medium types have less influence towards the cell proliferation; 
while the presence of IGF-1did induce more proliferation 
50
, as what have been shown in 
Figure A1A (in Appendix). Generally, high glucose level could suppress the 
mineralization (an indication for osteogenesis at late stage) in mesenchymal stem cells 
through inhibition of osteogenic markers such as ALP, Runx2 and OCN 
51-53
. However, 
in the present study, mineralization could still be visualized by alizarin red s staining, 
though less calcium deposition and lower Runx2 expression were observed as compared 
to control (DM3, low glucose DMEM). This phenomenon might be due to the 
compensatory effect of the presence of IGF-1, which could promote higher Runx2 
expression compared to the empty scaffolds 
54-56
, as shown in Figure A1B ( in Appendix). 
In conclusion, TE85 could proliferate well regardless of the medium types used; however, 
the osteogenic supplements are essential in promoting mineralization when TE85s were 
cultured in high glucose environment for the subsequent tri-culture experiments. 
In vitro tri-culture muscle/tendon/bone model Chapter 6 
110 
 
 
Lastly, for the culture of tendon cells, tenocytes have shown similar proliferation rate 
while being cultured in both types of growth medium (i.e. GM1 and GM2). They were 
further subjected to optimized differentiation medium (i.e. GM5, high glucose DMEM 
with osteogenic supplements, after optimization from C2C12 and TE85 differentiation 
studies) and their tendency to differentiate was evaluated by using checking the 
expression of tendon specific genes, which are scleraxis, tenomodulin and collagen I 
respectively. Though all three genes were slightly down-regulated (but not significantly) 
as compared to control (i.e. cultured in tenocytes original medium), the tenocytes were 
still able to survive, proliferate, maintain their typical elongated morphology on IGF-1 
scaffold, as visualized by the cytoskeleton staining. The final experiments showed that 
C2C12 cells could reside on one end of the scaffold while showing differentiation 
through the immunolabeling of myogenin; TE85 cells could reside on the other end while 
showing differentiation through labeling of Runx2 markers and tenocytes survived at the 
centre part of the scaffold after culturing for 1 week (3 days for proliferation phase and 4 
days for differentiation). This is the first study to show that three types of cells could 
proliferate and differentiate in one general medium, mimicking the actual 
musculoskeletal tissue arrangement 
57
. With such outcome, it would be interesting to use 
this study as the platform to further explore how cells interact with each other and how to 
improve the interaction among different types of cell in future experiments. 
 
6.5 Summary 
 
C2C12, tenocytes and TE85 were cultured on the same scaffold and under the same 
medium environment. PicoGreen analysis, PCR results and immunolabeling of 
differentiation markers have shown that these three types of cells could survive, 
proliferate and differentiate under the optimized medium conditions. Although the 
interaction among the cells was not explored, the co-existence of these three types of cell 
in one environment implies that the possibility for re-creating the muscle-tendon-bone 
configuration in vitro. With the knowledge obtained from this in vitro musculoskeletal 
model, the quality of the biological tools and the approaches for therapeutic agents‘ 
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discovery could be significantly improved. 
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Chapter 7  
 
Conclusions and Recommendations 
 
This chapter firstly relates the two hypotheses to the findings in this work 
and discusses on how objectives were thus achieved. Recommendations on 
the possible future work as a continuation to the various findings of this 
work were then suggested at the later sections. 
 
.
Conclusion and Recommendations  Chapter 7 
116 
 
7.1 Conclusion 
 
The aim of this dissertation was to address the issues which might defer the success of 
tendon healing via tendon tissue engineering (TE) approach, namely postoperative 
adhesions, improper healing due to lack of endogenous biochemical cues and failure in 
recreating the translational junctions between muscle-tendon-bone. Despite the fact that 
numerous efforts have been attempted, such as improving tendon healing through 
scaffolds with tendon characteristics (i.e. alignment to provide morphological cues, 
mechano-stimulation, chemical stimulation or appropriate cell types, these 
abovementioned issues might pose as threat in deferring the success of tendon healing. 
Thus, with the knowledge in delivering therapeutics, we thus develop a sustained dual 
therapy for accelerating tendon healing.  
 
The first objective, which is to obtain sustained release of naproxen sodium (NPS) in an 
electrospun fibrous scaffold in order to address the postoperative adhesions, was achieved. 
XPS analysis showed that when minimal amount of water was used at 3v/v% as the co-
solvent, less NPS was detected on the fiber surface, indicating that more NPS prefer to 
reside into the inner region of the fibers and hence slower release was obtained and lasted 
for two weeks. This supports the first hypothesis of the dissertation that sustained release 
of NPS was realized through affecting the distribution of the NPS via modulating the 
polymer compositions and co-solvent (i.e. water) used. However, NPS was found to be 
released faster with the increase of H2O content. When increasing the water content, 
thinner fibers were produced. A higher release rate of NPS was observed with the thinner 
fibers, which have higher surface area to volume ratio. Therefore, the NPS release rate is 
relied on a balance between the fiber thickness and solvents evaporation rate. Besides, the 
scaffolds possessed desirable characteristics for tendon TE, such as aligned fibrous 
morphology and good mechanical properties. The preliminary cell studies showed that 
L929 proliferated healthily indicating the scaffolds had no cytotoxicity issues. In addition, 
tenocytes could respond to the topographical cues given by the aligned fibrous scaffolds, 
forming a network of cells which mimic the native tendon tissue arrangement. Despite 
the beneficial role of NPS in preventing adhesions, NPS has inhibitory effects towards 
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tenocytes proliferation. Nonetheless, the release insulin-like growth factor 1 (IGF-1) from 
the combined scaffolds in the subsequent study recovered this phenomenon. It would be 
of further interest if study could be done to examine the effect of released NPS in 
preventing the adhesion formations in the actual tendon healing. This will be discussed in 
the recommendation section. 
 
The second objective of this dissertation is to achieve controlled release of IGF-1 to 
improve the tendon healing. Growth factors (GFs, such as IGF-1) are important in 
stimulating cellular growth and maturation, but GFs have short half life in vivo and hence 
it is necessary to deliver GFs sustainably. However, current approaches in delivering GFs 
generally deteriorate the protein stability. In view of this, HFIP has been utilized as it was 
found that HFIP could better preserve IGF-1 stability (~80%) and western blot analysis 
has indicated that the released IGF-1 remained bioactive. These have proven the 
hypothesis that IGF-1 bioactivity could be better preserved through the use of HFIP as 
electrospinning solutions. Notably, a 10-week controlled release of IGF-1 was achieved 
via adjusting the electrospinning solution formulations. The released IGF-1 was also able 
to promote downstream cellular responses, such as enhancing the tenocytes proliferation 
and differentiation. Although tenocytes proliferated slower in NPS environment, the 
released IGF-1 could rescue the NPS inhibitory effect by promoting tenocytes 
proliferation. This dual-release scaffold hence has the potential to enhance the tendon 
healing, firstly by reducing the adhesion formation and at the same time promoting 
tendon cells growth under the influence of scaffolds‘ topographical cues to mimic the 
native tendon tissue arrangement. 
 
The third objective was to address the difficulty in regenerating the translational region 
between muscle-tendon-bone connections. In view of the necessity to provide proper 
environment for the growth and maturation of different tissue types, the culture 
conditions (in terms of medium glucose level and supplements for inducing 
differentiation) have been optimized. It was shown that three different cell types could 
grow and mature on the IGF-1 scaffold to allow the formation of muscle-tendon-bone 
configuration, similar to how it is arranged in the native human body. This study focused 
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on the medium compatibility optimization, which proved the concept of cultivating three 
types of cells in vitro under same environment. Further studies, such as improving 
interactions between cells and the related functional study, could be done to ameliorate 
this musculoskeletal model. This will be further discussed in the recommendations 
section. 
 
As a summary, a scaffold which has tendon characteristics, such as aligned morphology 
and optimal mechanical properties, and the ability to release IGF-1 sustainably for 10 
weeks was successfully fabricated. In order to address postoperative adhesion formations, 
NPS was loaded and 2-week sustained release was achieved. IGF-1 scaffold demonstrates 
the feasibility to compensate the inhibitory effect posed by NPS, though the latter has 
beneficial effcct in preventing adhesion formation. At the same time, this IGF1 scaffold  
can be served as a platform for cultivating different cell types to promote the regeneration 
at the muscle-tendon-bone connections. The proposed approaches can either be applied 
separately or combined together in order to better promote tendon healing (Figure 7.1). 
 
Figure 7.1: Schematic showing how proposed solutions addressed the problem statement to improve 
tendon healing  
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7.2 Recommendations 
 
7.2.1 Three dimensional (3D) scaffolds to better represent cellular micro-
environment 
 
Despite the fact that cellular responses in this dissertation demonstrated the great 
potential of the presented scaffolds (which released NPS and IGF-1 simultaneously) in 
promoting tendon healing, these results may not be entirely representative to the actual 
cellular environment. This is because the cells were actually subjected to a semi 3D 
scaffolds as fabricated by the electrospinning technique, where the extent of cell 
penetration into the scaffolds is limited 
1,2
. The fabrication of 3D scaffolds arouses a lot 
of interests as the cellular response (such as cell morphogenesis, cell-cell interactions and 
migration) from in vitro study using 3D scaffolds could hence be better correlated to the 
actual organs or tissues. Several methods such as multi-layering 
3-5
, post-processing 
6-8
, 
porogen-assisted 
9,10
, liquid-assisted 
11
 
12
 or self-assembly 
13,14
 methods could be further 
explored to create 3D scaffolds for tendon TE by using electrospinning technique. 
Notably, most optimizations relating to electrospinning 3D scaffolds are involved in 
introducing sufficient spaces to allow cell penetration through additional processes, 
where the fibers forming step is generally unchanged. This implies that the 
aforementioned methods will have less effect in affecting the fabrication of previously 
optimized drugs-loaded scaffolds. By having 3D scaffolds, scientists will be able to 
regulate the cell cycle or tissue formation more effectively to improve the living 
expectancy of human beings. 
  
7.2.2 Integration with interface tissue engineering to promote interactions between 
different cell types 
 
This dissertation demonstrated the feasibility of tri-culture of different cell types via 
medium compatibility optimization. Although Figure 6.12 showed that three cell types 
could survive, proliferate, differentiate and the muscle-tendon-bone configuration could 
be achieved to mimic the actual musculoskeletal arrangement in vivo, there was no 
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interaction study done between different cell types. To properly address the regeneration 
issue at this intricate, translational region, cells should be allowed to have cross-talk in 
order to promote integration. Hence, it is suggested that further studies should work 
closely with interface tissue engineering, which aims to re-establish the continuous 
interface and to facilitate the integration between different tissue types through tissue 
engineering approach. From the aspect of scaffold designing approach, the drug-loaded 
fibers could be produced into a transitional fibrous scaffold with ―aligned-to-random‖ 
features, to mimic the collagen fibers organization at the tendon-to-bone insertion site 
15,16
. Secondly, it would be of interest if the cells are allowed to have longer time to 
migrate and interact, or smaller separator could be used to allow more cellular 
interactions. At the integration site, further analysis such as collagen or calcium 
depositions should be analyzed to investigate if the unique translational tissue formation 
could be reproduced at this region in vitro 
17-19
. 
 
7.2.3 In-depth evaluation on the timely-released-NPS scaffolds for prevention of 
adhesions in animal models 
 
Several studies have shown the adhesion formations could be improved through the use 
of non-steroidal anti-inflammatory drug, such as NPS in the animal models 
20
. In contrast, 
other researchers demonstrated that NPS had deleterious effects in terms of tissues 
healing 
21
. This paradox implies that the optimal therapeutic dosage which could address 
the adhesion formation without inhibiting tissues healing is yet to be confirmed in vivo. A 
controllable and sustained-release system as demonstrated in this dissertation could hence 
become a platform to understand the optimal continuous dosage needed to prevent 
adhesion formations by having continuous stimulations to the injury sites.  
 
One of the options to evaluate the efficacy of released NPS could be culturing 
macrophages as an indication for the possibility of the associated inflammation process. 
Being inflammatory cells, macrophages are recruited into synovial sheath and epitenon 
and initialize the subsequent inflammation responses, leading to the adhesion formations 
in the body 
22,23
. Hence, through understanding the cellular response (such as 
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proliferation and apoptosis) on the sustained-release system in this dissertation, we can 
further determine the dosage required for preventing adhesion formations. Besides, for in 
vivo approach, other than evaluating the inflammatory cells related genes expression 
(such as Cox-2) at the injury site 
24
, the adhesion coefficient (i.e. to measure the degree of 
metatarsophalangeal joint range of motion with increasing loads) could be used to justify 
the extent of adhesion formations 
25,26
. Besides, biomechanical properties of the 
regenerated tendons from animal models could be also assessed to understand the 
efficacy of the released NPS. 
 
7.2.4  Animal studies on dual-release scaffolds to better promote tendon healing 
 
In this dissertation, the possibility of released IGF-1 in rescuing the NPS inhibitory effect 
on tenocytes proliferation has been demonstrated. This has suggested that this dual-
release scaffold could have the advantageous effect in preventing adhesion formations 
and promoting tendon cell proliferations and maturation simultaneously. Therefore 
further studies involving in vivo work on the dual-release scaffold is recommended, so as 
to check on their actual effect in promoting tendon healing. The following is some 
suggested studies to evaluate the proposed in vivo work:  
 
1) For the evaluation of efficacy of NPS, please refer to animal studies in section 7.2.3; 
 
2) To examine the proliferative effect on IGF-1 in the animal models in order to confirm 
the regenerative response rather than scar formation response, tendon specific genes such 
as scleraxis and tenomodulin would be analyzed on their expressions and localizations in 
the injury sites 
27,28
.  
 
3) Type 3 collagen and type I collagen expressions which are associated with the tendon 
healing would also be determined to confirm the extracellular matrix deposition 
29,30
.  
 
4) The mechanical testing of the harvested tissues could also be done to examine the 
efficacy of the released IGF-1 
31
. 
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APPENDIX 
 
 
Figure A1: Graphs showing A) TE85 cells proliferated faster and B) Runx2 expression was up-
regulated, on IGF-1 scaffolds compared to empty scaffolds. (* indicates p < 0.05) 
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